Data / Research funding / Skin Cancer
Skin Cancer: 515 NIH awards ($642.9M) to 152 organizations
515 NIH awards ($642.9M) in the NIH spending category Skin Cancer, to 152 organizations, read 2026-11-03. NIH fiscal years 2021 to 2025.
SpecStream is the live web data engine for teams and agents. It reads the NIH and NSF award files each time the agencies update them, and this page is that reading, joined to the open federal funding opportunities on Grants.gov. Ask for the awards you track by topic, organization or state and new awards arrive in your sheet, CRM, Slack or agent as the agencies publish them.
- Topic
- NIH spending category
Awards
The 500 largest of 515 awards in the window.
| Award | Agency | Institute or division | Fiscal year | Amount in window | Start | End | Principal investigator | Source |
|---|---|---|---|---|---|---|---|---|
| Spatiotemporal Tumor Analytics for Guiding Sequential Targeted-Inhibitor: Immunotherapy Combinations (ST-Analytics) | NIH | National Cancer Institute | 2022 to 2025 | $10,596,037 | September 22, 2022 | August 31, 2027 | HEATH, JAMES R. | reporter.nih.gov |
| Biomarker Rich Clinical Trial of an Innovative Antibody Antagonist of TNFR2 in Non-Hodgkin Lymphoma Featuring Cutaneous T Cell Lymphoma (CTCL). | NIH | National Cancer Institute | 2021 to 2025 | $6,371,380 | September 1, 2021 | June 30, 2027 | BROOKS, DAVID G | reporter.nih.gov |
| NCTN Lead Academic Participating Site at Dana-Farber/Partners Cancer Care | NIH | National Cancer Institute | 2021 to 2025 | $5,422,908 | March 5, 2019 | February 28, 2026 | BURSTEIN, HAROLD JOHN | reporter.nih.gov |
| Pre-cancer atlas of skin cancer | NIH | National Cancer Institute | 2024 to 2025 | $5,182,743 | September 1, 2024 | August 31, 2029 | SHAIN, ALAN HUNTER | reporter.nih.gov |
| Identification of Novel Oncogenic Signaling Pathways using Viral Perturbations | NIH | National Cancer Institute | 2021 to 2025 | $5,173,906 | August 8, 2019 | July 31, 2026 | DECAPRIO, JAMES A. | reporter.nih.gov |
| Proteogenomic studies to understand mechanisms and drivers of resistance to immunotherapies | NIH | National Cancer Institute | 2022 to 2025 | $4,722,849 | June 16, 2022 | May 31, 2027 | PAULOVICH, AMANDA G | reporter.nih.gov |
| Next Generation Cancer Immunotherapies to Defeat Melanoma | NIH | National Cancer Institute | 2021 to 2025 | $4,577,719 | September 9, 2015 | August 31, 2029 | RIBAS, ANTONI | reporter.nih.gov |
| Genetic and molecular basis for variation in human skin pigmentation | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases | 2021 to 2024 | $4,362,884 | May 1, 2020 | April 30, 2026 | MARKS, MICHAEL S | reporter.nih.gov |
| Immune checkpoint inhibitors and accelerated coronary atherosclerosis | NIH | National Heart, Lung, and Blood Institute | 2022 to 2025 | $4,014,114 | May 1, 2022 | April 30, 2027 | NEILAN, TOMAS G | reporter.nih.gov |
| Structure, Function and Mechanistic Analysis of LAG3 | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,664,179 | January 8, 2019 | December 31, 2028 | VIGNALI, DARIO AA | reporter.nih.gov |
| Bioactive Metabolites Modulate Immune-Related Adverse Events in Cancer Immunotherapy | NIH | National Cancer Institute | 2021 to 2025 | $3,549,010 | July 8, 2021 | February 28, 2027 | SHARMA, SONIA | reporter.nih.gov |
| Identification of Lethal Melanomas at the Time of Diagnosis | NIH | National Cancer Institute | 2021 to 2024 | $3,546,906 | April 1, 2020 | March 31, 2026 | THOMAS, NANCY E. | reporter.nih.gov |
| Role of Trem1 in ultraviolet radiation-induced immune suppression | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,453,128 | June 18, 2021 | May 31, 2027 | YUSUF, NABIHA | reporter.nih.gov |
| Chemical tools for developmental biology | NIH | National Institute of General Medical Sciences | 2021 to 2025 | $3,426,216 | April 1, 2018 | June 30, 2028 | CHEN, JAMES K | reporter.nih.gov |
| Identifying modifiable factors that reduce the burden of late stage melanoma in Hispanics | NIH | National Cancer Institute | 2021 to 2025 | $3,286,805 | May 18, 2021 | April 30, 2027 | COCKBURN, MYLES G | reporter.nih.gov |
| Evaluation of an implantable microdevice for rapid cancer drug screening directly in T cell lymphoma patients | NIH | National Cancer Institute | 2021 to 2025 | $3,235,983 | July 1, 2020 | June 30, 2027 | LAROCCA, CECILIA | reporter.nih.gov |
| Immunotherapy Modeling in Organoids Co-preserving Tumor and Infiltrating Immune Compartments | NIH | National Cancer Institute | 2021 to 2025 | $3,224,380 | March 17, 2021 | February 28, 2027 | KUO, CALVIN J | reporter.nih.gov |
| Advancing skin cancer prevention by tackling UV-induced clonogenic mutations | NIH | National Cancer Institute | 2021 to 2025 | $3,218,488 | February 3, 2021 | January 31, 2027 | WEI, LEI | reporter.nih.gov |
| Pacritinib in rel/refr T-cell lymphomas | NIH | National Cancer Institute | 2021 to 2025 | $3,194,893 | September 1, 2021 | August 31, 2027 | WILCOX, RYAN A | reporter.nih.gov |
| Technology-Enabled Activation of Skin Cancer Screening for Hematopoietic Cell Transplantation Survivors and their Primary Care Providers | NIH | National Cancer Institute | 2021 to 2024 | $3,192,137 | April 1, 2020 | March 31, 2026 | ARMENIAN, SARO | reporter.nih.gov |
| CD4+ T cells and neoantigens in melanoma immunotherapy. | NIH | National Cancer Institute | 2021 to 2025 | $3,143,740 | December 1, 2020 | November 30, 2026 | WANG, RONGFU | reporter.nih.gov |
| Eco-evolutionary drivers of clonal dynamics during UV-induced skin carcinogenesis (PQ3) | NIH | National Cancer Institute | 2021 to 2025 | $3,142,500 | April 1, 2021 | March 31, 2027 | TSAI, KENNETH Y | reporter.nih.gov |
| Small molecule enhancers of tumor immunity targeting the LPA5 GPCR | NIH | National Cancer Institute | 2022 to 2025 | $3,114,085 | August 1, 2022 | July 31, 2026 | TIGYI, GABOR J | reporter.nih.gov |
| Fast, large area, multiphoton exoscope (FLAME) for improving early detection of melanoma | NIH | National Cancer Institute | 2022 to 2025 | $3,098,530 | September 1, 2022 | August 31, 2027 | BALU, MIHAELA | reporter.nih.gov |
| Mechanisms of cAMP-dependent regulation of melanosome pH | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases | 2021 to 2025 | $3,089,547 | April 1, 2021 | March 31, 2026 | ZIPPIN, JONATHAN HALE | reporter.nih.gov |
| M-ISIC: A Multimodal Open-Source International Skin Imaging Collaboration Informatics Platform for Automated Skin Cancer Detection | NIH | National Cancer Institute | 2022 to 2025 | $3,081,926 | September 1, 2022 | August 31, 2027 | ROTEMBERG, VERONICA MIRIAM | reporter.nih.gov |
| Quantitative assessment of pre-metastatic immune subversion as a risk factor for melanoma relapse | NIH | National Cancer Institute | 2022 to 2025 | $3,027,575 | September 1, 2022 | August 31, 2027 | MARKOVIC, SVETOMIR NENAD | reporter.nih.gov |
| Pivotal Clinical Study of the TruScore Device for Non-Invasive Skin Cancer Diagnostics | NIH | National Cancer Institute | 2022 to 2024 | $2,999,584 | May 1, 2016 | June 30, 2026 | CHACHISVILIS, MIRIANAS | reporter.nih.gov |
| PD-1/PD-L1 modulation in cancer therapy | NIH | National Cancer Institute | 2021 to 2025 | $2,958,687 | June 21, 2010 | February 28, 2027 | PARDOLL, DREW M. | reporter.nih.gov |
| Phase II Clinical Development of Galectin-3 Inhibition and Anti-PD-1: Immune Monitoring and Tumor Response | NIH | National Cancer Institute | 2021 to 2025 | $2,952,871 | August 2, 2021 | July 31, 2027 | CURTI, BRENDAN D | reporter.nih.gov |
| A Registry-Based Study of Patterns of Use of Targeted Therapies for Metastatic Cancers in Diverse Populations | NIH | National Cancer Institute | 2021 to 2025 | $2,899,424 | May 1, 2021 | November 30, 2025 | VEENSTRA, CHRISTINE | reporter.nih.gov |
| Development of First-in-Class RIPK1 Degraders to Improve Cancer Immunotherapies | NIH | National Cancer Institute | 2022 to 2025 | $2,872,577 | July 7, 2022 | September 2, 2025 | WANG, JIN | reporter.nih.gov |
| Activation of the DNA-PK-dependent antiviral response as a novel cancer immunotherapy | NIH | National Cancer Institute | 2022 to 2025 | $2,795,412 | January 20, 2022 | December 31, 2026 | STETSON, DANIEL B | reporter.nih.gov |
| Tissue Resident memory T cell responses to cancer | NIH | National Cancer Institute | 2021 to 2025 | $2,755,604 | February 12, 2018 | June 30, 2028 | TURK, MARY JO | reporter.nih.gov |
| [18F]4FN PET Imaging of Innate Immunity Activation During Immunotherapy-Induced Adverse Events | NIH | National Cancer Institute | 2022 to 2025 | $2,714,023 | September 1, 2022 | August 31, 2027 | PIWNICA-WORMS, DAVID | reporter.nih.gov |
| Gamma delta T cell based melanoma therapies | NIH | National Cancer Institute | 2022 to 2025 | $2,700,439 | December 13, 2021 | November 30, 2026 | XU, XIAOWEI | reporter.nih.gov |
| Multiscale Modeling to Optimize Inhibition of Oncogenic ERK Pathway Signaling | NIH | National Cancer Institute | 2021 to 2024 | $2,681,014 | February 7, 2020 | January 31, 2025 | LEMMON, MARK A | reporter.nih.gov |
| Cancer Resistant Mice | NIH | National Cancer Institute | 2022 to 2025 | $2,674,668 | December 1, 2021 | November 30, 2026 | BEUTLER, BRUCE A | reporter.nih.gov |
| Immunity to commensal papillomaviruses for cancer therapy | NIH | National Cancer Institute | 2021 to 2025 | $2,645,679 | May 1, 2021 | April 30, 2027 | DEMEHRI, SHADMEHR | reporter.nih.gov |
| Targeting Lymph Node Dependent Immune Tolerance in Cancer | NIH | National Cancer Institute | 2021 to 2025 | $2,643,851 | April 1, 2021 | March 31, 2026 | ENGLEMAN, EDGAR G. | reporter.nih.gov |
| Role of progenitor exhausted CD8 T cells and the progenitor niche in anti-PD1 efficacy | NIH | National Cancer Institute | 2022 to 2025 | $2,633,070 | September 1, 2022 | August 31, 2027 | HUANG, ALEXANDER | reporter.nih.gov |
| T-cell intrinsic mechanisms of resistance to PD-1 checkpoint blockade | NIH | National Cancer Institute | 2021 to 2024 | $2,596,957 | April 1, 2020 | March 31, 2025 | KROGSGAARD, MICHELLE | reporter.nih.gov |
| Resistance mechanisms to autophagy-modulating therapies | NIH | National Cancer Institute | 2022 to 2025 | $2,587,243 | February 15, 2022 | January 31, 2027 | AMARAVADI, RAVI K | reporter.nih.gov |
| Defining the role of NF1 and SPRED1 loss in melanoma | NIH | National Cancer Institute | 2021 to 2025 | $2,567,516 | April 1, 2020 | April 30, 2027 | YEH, IWEI | reporter.nih.gov |
| Neoadjuvant Immunotherapy with Intratumoral CPG and PD-1 Blockade in Melanoma | NIH | National Cancer Institute | 2021 to 2025 | $2,557,993 | March 1, 2021 | February 28, 2027 | ZAROUR, HASSANE M | reporter.nih.gov |
| Genome-wide mutational integration for ultra-sensitive plasma tumor burden monitoring in immunotherapy | NIH | National Cancer Institute | 2022 to 2025 | $2,537,016 | June 1, 2022 | May 31, 2027 | LANDAU, DAN | reporter.nih.gov |
| Functional analysis of a novelintegrin-dependent metastasis pathway in melanoma | NIH | National Cancer Institute | 2021 to 2025 | $2,532,647 | December 1, 2020 | November 30, 2025 | SCHATTON, TOBIAS | reporter.nih.gov |
| Anti-tumor immunity and intestinal microbiota are modulated by mitochondrial DNA | NIH | National Cancer Institute | 2022 to 2025 | $2,514,943 | May 1, 2022 | April 30, 2027 | WALLACE, DOUGLAS C | reporter.nih.gov |
| Dissecting Phenotype Switching in Early Stage Melanomas | NIH | National Cancer Institute | 2022 to 2025 | $2,502,851 | August 4, 2022 | July 31, 2027 | SCHOBER, MARKUS | reporter.nih.gov |
| Targeting Aldehyde Dehydrogenase for Cancer Prevention | NIH | National Cancer Institute | 2021 to 2024 | $2,499,798 | April 15, 2020 | March 31, 2026 | ROBERTSON, GAVIN P. | reporter.nih.gov |
| Stromal Regulation of Basal Cell Carcinoma Formation | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases | 2021 to 2025 | $2,499,266 | July 1, 2001 | March 31, 2027 | ORO, ANTHONY E | reporter.nih.gov |
| The Adenosinergic Pathway in Tumor-derived Exosomes | NIH | National Cancer Institute | 2021 to 2025 | $2,474,457 | April 1, 2021 | March 31, 2027 | WHITESIDE, THERESA L. | reporter.nih.gov |
| Toward translation of a plant virus-based in situ vaccination nanotechnology | NIH | National Cancer Institute | 2022 to 2025 | $2,469,213 | August 22, 2022 | July 31, 2026 | STEINMETZ, NICOLE FRANZISKA | reporter.nih.gov |
| Targeting S6K2 to Overcome Drug Resistance in NRAS-mutant Melanoma | NIH | National Cancer Institute | 2022 to 2025 | $2,440,545 | September 1, 2022 | August 31, 2027 | VILLANUEVA, JESSIE | reporter.nih.gov |
| Rapid Sample-to-Answer Diagnosis of Kaposi's Sarcoma Across Sub-Saharan Africa using KS-COMPLETE | NIH | National Cancer Institute | 2022 to 2025 | $2,409,286 | June 10, 2022 | May 31, 2027 | ERICKSON, DAVID CARL | reporter.nih.gov |
| Impact of microbiota on AIDS-Kaposi’s sarcoma development and therapy | NIH | National Cancer Institute | 2023 to 2025 | $2,362,235 | September 8, 2023 | August 31, 2028 | GAO, SHOU-JIANG | reporter.nih.gov |
| An integrated polymeric carrier for subunit cancer vaccines | NIH | National Cancer Institute | 2021 to 2025 | $2,360,660 | March 5, 2021 | February 28, 2027 | PUN, SUZIE H. | reporter.nih.gov |
| MITF from control of pigmentation to melanoma risk | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases | 2021 to 2025 | $2,355,687 | February 20, 1996 | February 29, 2028 | FISHER, DAVID E | reporter.nih.gov |
| Epigenetic control of skin homeostasis by the ULK3 nuclear kinase | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases | 2021 to 2025 | $2,352,166 | August 1, 2021 | April 30, 2026 | DOTTO, GIAN-PAOLO | reporter.nih.gov |
| Advancing Precision Oncology in a Humanized, Fully Autologous Mouse Model | NIH | National Cancer Institute | 2021 to 2024 | $2,342,069 | March 1, 2020 | February 28, 2026 | FIELDS, RYAN C | reporter.nih.gov |
| Combating melanoma resistance by targeting ABL1/2 | NIH | National Cancer Institute | 2022 to 2025 | $2,341,643 | May 23, 2022 | April 30, 2027 | PLATTNER, RINA | reporter.nih.gov |
| Mechanisms of cell death in cutaneous melanoma | NIH | National Cancer Institute | 2021 to 2025 | $2,341,029 | June 15, 2021 | May 31, 2027 | APLIN, ANDREW ERIC | reporter.nih.gov |
| Understanding and Overcoming Resistance to BRAF/MEK Kinase Inhibitors in Melanoma | NIH | National Cancer Institute | 2021 to 2024 | $2,327,927 | December 13, 2019 | November 30, 2025 | RAJ, ARJUN | reporter.nih.gov |
| Systems analysis of cell-cell communication networks and immune activity in the melanoma tumor microenvironment | NIH | National Cancer Institute | 2021 to 2024 | $2,320,897 | July 1, 2020 | June 30, 2025 | MILLER-JENSEN, KATHRYN | reporter.nih.gov |
| Correlative biomarkers of IL-6 blockade combined with checkpoint inhibition | NIH | National Cancer Institute | 2021 to 2024 | $2,320,161 | July 2, 2020 | June 30, 2025 | MEHNERT, JANICE M. | reporter.nih.gov |
| Regulating Gli Function in Hair Follicle Progenitors | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases | 2021 to 2025 | $2,320,049 | May 7, 2007 | December 31, 2027 | ORO, ANTHONY E | reporter.nih.gov |
| A personalized approach to skin cancer prevention among adolescents | NIH | National Cancer Institute | 2021 to 2024 | $2,317,171 | March 1, 2020 | February 28, 2026 | WU, YELENA PING | reporter.nih.gov |
| Functional and Therapeutic Significance of PLK4 in Melanoma | NIH | National Cancer Institute | 2022 to 2025 | $2,316,913 | July 25, 2022 | June 30, 2027 | AHMAD, NIHAL | reporter.nih.gov |
| Role of Desmoglein 1 in Keratinocyte-Melanocyte Communication and Melanoma | NIH | National Cancer Institute | 2021 to 2025 | $2,314,190 | February 1, 2019 | February 28, 2029 | GREEN, KATHLEEN JANEE | reporter.nih.gov |
| Identification and assessment of unconventional tumor-associated antigens as potential targets for cytotoxic T-cell based immunotherapy of cancer | NIH | National Cancer Institute | 2022 to 2025 | $2,299,787 | July 1, 2022 | June 30, 2027 | LIZEE, GREGORY A | reporter.nih.gov |
| The regulation of melanocyte stem cells by Wnt signaling | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases | 2021 to 2025 | $2,297,460 | August 5, 2011 | July 31, 2026 | ITO, MAYUMI | reporter.nih.gov |
| Cell type-directed Tim-3 targeting in melanoma | NIH | National Cancer Institute | 2022 to 2025 | $2,295,658 | June 1, 2022 | May 31, 2027 | BARTHEL, STEVEN RUSSELL | reporter.nih.gov |
| Characterizing and predicting colitis in immune checkpoint blockade-treated cancer patients | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2024 | $2,286,893 | June 1, 2020 | May 31, 2026 | GNJATIC, SACHA | reporter.nih.gov |
| Discovery of Glutaryl-CoA Dehydrogenase inhibitors for melanoma and pancreatic cancer | NIH | National Cancer Institute | 2022 to 2025 | $2,285,106 | December 8, 2021 | November 30, 2025 | SERGIENKO, EDUARD A. | reporter.nih.gov |
| Identification and characterization of cancer cell states by novel computational and experimental technologies - Resubmission - 1 | NIH | National Cancer Institute | 2022 to 2025 | $2,279,461 | June 21, 2022 | May 31, 2027 | YANAI, ITAI | reporter.nih.gov |
| Chromosome 1q ceRNAs in Melanoma Progression and Metastasis | NIH | National Cancer Institute | 2021 to 2025 | $2,273,687 | May 1, 2021 | April 30, 2027 | KARRETH, FLORIAN | reporter.nih.gov |
| Androgen receptor signaling and sex differences in anti-tumor dendritic cell function | NIH | National Cancer Institute | 2025 | $2,265,578 | September 23, 2025 | August 31, 2029 | RUHLAND, MEGAN K | reporter.nih.gov |
| The Aging Cutaneous Microenvironment and Cancer Initiation | NIH | National Institute on Aging | 2021 to 2025 | $2,262,646 | September 30, 2021 | May 31, 2026 | FISHER, GARY J | reporter.nih.gov |
| Development of selective HDAC6 inhibitors to improve cancer immunotherapy | NIH | National Cancer Institute | 2022 to 2025 | $2,260,714 | February 1, 2021 | January 31, 2026 | VILLAGRA, ALEJANDRO V | reporter.nih.gov |
| Androgen receptor function in melanoma | NIH | National Cancer Institute | 2022 to 2025 | $2,253,887 | September 23, 2022 | August 31, 2027 | DOTTO, GIAN-PAOLO | reporter.nih.gov |
| Small-molecule exploitation of ZBP1-driven nuclear necroptosis for cancer immunotherapy | NIH | National Cancer Institute | 2023 to 2025 | $2,239,005 | January 1, 2023 | December 31, 2027 | BALACHANDRAN, SIDDHARTH | reporter.nih.gov |
| Post-translational SOX2 modification - a regulatory switch between self-renewal and differentiation in squamous cell carcinoma | NIH | National Cancer Institute | 2021 to 2025 | $2,223,749 | December 1, 2020 | November 30, 2025 | SCHOBER, MARKUS | reporter.nih.gov |
| A Platform Technology to Genetically Reprogram Cancer Cells for Enhanced Immunotherapy | NIH | National Cancer Institute | 2021 to 2025 | $2,221,249 | July 1, 2025 | June 30, 2027 | TZENG, STEPHANY YI | reporter.nih.gov |
| Mechanisms of liver metastasis and associated resistance to immunotherapy | NIH | National Cancer Institute | 2021 to 2025 | $2,220,950 | March 9, 2021 | February 28, 2026 | IZAR, BENJAMIN | reporter.nih.gov |
| Skin cancer on social media: Analyzing current communications, modeling diffusion potential, and developing innovative prevention-focused messages | NIH | National Cancer Institute | 2024 to 2025 | $2,164,376 | September 3, 2024 | August 31, 2028 | WALSH-BUHI, ERIC RICHARD | reporter.nih.gov |
| Role of circular RNA CDR1as in melanoma | NIH | National Cancer Institute | 2021 to 2024 | $2,159,990 | March 2, 2020 | February 28, 2025 | HERNANDO, EVA | reporter.nih.gov |
| Role of S.aureus in Cutaneous T Cell Lymphoma Pathogenesis | NIH | National Cancer Institute | 2022 to 2025 | $2,150,022 | May 10, 2022 | April 30, 2027 | KORALOV, SERGEI BORISOVICH | reporter.nih.gov |
| Cell adhesion and tissue dynamics in the skin | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases | 2023 to 2025 | $2,136,170 | December 1, 1980 | August 31, 2028 | FUCHS, ELAINE | reporter.nih.gov |
| Sustaining Tissue Resident Memory T cells | NIH | National Cancer Institute | 2022 to 2025 | $2,112,390 | January 1, 2022 | December 31, 2026 | HUANG, YINA HSING | reporter.nih.gov |
| Coordinated Cytoskeletal Dynamics and Membrane Remodeling in Cellular Shape Change | NIH | National Institute of General Medical Sciences | 2021 to 2025 | $2,110,101 | December 1, 2019 | November 30, 2029 | GUPTON, STEPHANIE | reporter.nih.gov |
| Using dietary glutamine supplementation for melanoma prevention and targeted therapy | NIH | National Cancer Institute | 2021 to 2025 | $2,095,124 | July 1, 2021 | June 30, 2027 | KONG, MEI | reporter.nih.gov |
| Multimodal confocal microscopy for surgical guidance of skin resections | NIH | National Cancer Institute | 2022 to 2025 | $2,090,817 | August 1, 2022 | July 31, 2027 | TUNNELL, JAMES W | reporter.nih.gov |
| Clinical evaluation of a novel AKT/PDK1 inhibitor, PHT-427, for the treatment of multi-field actinitc keratoses | NIH | National Cancer Institute | 2025 | $2,085,765 | September 15, 2025 | August 31, 2027 | POWIS, GARTH | reporter.nih.gov |
| Genome-wide analysis of the formation and mutagenesis of atypical UV photoproducts in skin cancer | NIH | National Institute of Environmental Health Sciences | 2021 to 2025 | $2,084,325 | April 1, 2021 | June 19, 2026 | WYRICK, JOHN J | reporter.nih.gov |
| Mitochondrial lateral transfer during metastasis | NIH | National Cancer Institute | 2021 to 2025 | $2,081,728 | February 1, 2021 | January 31, 2026 | ROH, MINNA | reporter.nih.gov |
| Multi-cellular interactions defining the human brain metastatic niche | NIH | National Cancer Institute | 2023 to 2025 | $2,058,782 | May 1, 2023 | April 30, 2028 | IZAR, BENJAMIN | reporter.nih.gov |
| Cell fate decisions in Merkel cell carcinoma initiation and maintenance | NIH | National Cancer Institute | 2021 to 2024 | $2,054,205 | February 20, 2020 | January 31, 2025 | DLUGOSZ, ANDRZEJ A. | reporter.nih.gov |
| Innovative Research for Cancer Nanotechnology (IRCN) for Enhancing Melanoma-specific Immune Responses by the Rational Design of Spherical Nucleic Acids | NIH | National Cancer Institute | 2022 to 2025 | $2,035,485 | March 14, 2022 | February 28, 2027 | MIRKIN, CHAD A. | reporter.nih.gov |
| Advanced Surgical Pathology Device | NIH | National Cancer Institute | 2023 to 2024 | $2,027,951 | August 1, 2019 | April 30, 2026 | GAREAU, DANIEL SUMMER | reporter.nih.gov |
| Mutational Signatures of a Combined Environmental Exposure: Arsenic and Ultraviolet Radiation | NIH | National Institute of Environmental Health Sciences | 2021 to 2024 | $2,018,372 | April 6, 2020 | January 31, 2026 | HUDSON, LAURIE G | reporter.nih.gov |
| Defining epigenetic regulators of tumor heterogeneity and metastasis in melanoma | NIH | National Cancer Institute | 2022 to 2025 | $2,015,559 | July 5, 2022 | June 30, 2027 | HERNANDO, EVA | reporter.nih.gov |
| The role of the CD58:CD2 axis in cancer immune evasion and resistance to immunotherapy | NIH | National Cancer Institute | 2022 to 2025 | $2,007,768 | September 1, 2022 | August 31, 2027 | FRANGIEH, CHRISTOPHER | reporter.nih.gov |
| A Convergent Node in Melanoma to Block Multiple Oncogenic Pathways Simultaneously | NIH | National Cancer Institute | 2021 to 2024 | $2,007,018 | July 1, 2020 | June 30, 2025 | KWONG, LAWRENCE | reporter.nih.gov |
| Targeting the vasculature to enhance anti-tumor immunity | NIH | National Cancer Institute | 2021 to 2025 | $2,001,230 | September 1, 2014 | June 30, 2030 | DUDLEY, ANDREW CARL | reporter.nih.gov |
| A Phase 2, randomized, double-blind, 4-arm, multicenter study to demonstrate the efficacy and safety of topical dosage formulations of a prescription drug product for actinic keratosis | NIH | National Cancer Institute | 2023 to 2024 | $2,000,000 | September 14, 2023 | August 31, 2025 | ISAACMAN, STEVEN | reporter.nih.gov |
| Programming Metabolically Fit TILs for Immunotherapy | NIH | National Cancer Institute | 2023 to 2024 | $2,000,000 | February 15, 2020 | August 31, 2025 | MEHROTRA, SHIKHAR | reporter.nih.gov |
| Immunotherapy to deplete key Treg subsets in solid tumors | NIH | National Cancer Institute | 2024 to 2025 | $2,000,000 | August 13, 2024 | July 31, 2027 | SUZDAK, PETER DAVID | reporter.nih.gov |
| Noninvasive prediction of skin precancer severity using in vivo cellular imaging and deep learning algorithms. | NIH | National Cancer Institute | 2023 to 2024 | $1,999,298 | July 1, 2023 | May 31, 2025 | SANCHEZ, GABRIEL NESTOR | reporter.nih.gov |
| Regulation of stem-like CD8+ T cells and their role in immunotherapy | NIH | National Cancer Institute | 2021 to 2025 | $1,999,210 | March 1, 2015 | April 30, 2027 | ANDERSON, ANA C | reporter.nih.gov |
| 7HP349, an Integrin Activator to Treat Patients With anti-PD-1 Resistant Solid Tumors | NIH | National Cancer Institute | 2023 to 2024 | $1,998,400 | September 19, 2023 | August 31, 2025 | MARATHI, UPENDRA | reporter.nih.gov |
| Regulation of the ERK signaling pathway by K63-linked polyubiquitination | NIH | National Cancer Institute | 2022 to 2025 | $1,994,802 | September 9, 2022 | August 31, 2027 | YANG, XIAOLU | reporter.nih.gov |
| Re-engineering differential regulation of ferroptosis in melanoma microenvironment | NIH | National Cancer Institute | 2023 to 2025 | $1,975,612 | July 12, 2023 | June 30, 2028 | BUNIMOVICH, YURI | reporter.nih.gov |
| Gasdermin E and pyroptosis in cancer | NIH | National Cancer Institute | 2021 to 2024 | $1,970,899 | April 3, 2020 | March 31, 2025 | LIEBERMAN, JUDY | reporter.nih.gov |
| Defining the role of innate immune cells in the early stages of immune surveillance of skin cancer by using a novel model that allows in vivo imaging of the immunoediting process. | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases | 2022 to 2025 | $1,968,500 | September 15, 2022 | August 31, 2027 | ROOP, DENNIS | reporter.nih.gov |
| Translation of commensal bacteria mechanism for immunotherapy | NIH | National Cancer Institute | 2021 to 2024 | $1,965,036 | December 2, 2019 | November 30, 2024 | HANG, HOWARD C | reporter.nih.gov |
| Dual-isotope SPECT imaging and immunophenotyping of immune cells to determine response to immunotherapy | NIH | National Cancer Institute | 2023 to 2025 | $1,963,130 | February 7, 2023 | January 31, 2028 | KLUGER, HARRIET M. | reporter.nih.gov |
| Identifying Therapeutic Targets for Stage III Melanoma | NIH | National Cancer Institute | 2021 to 2024 | $1,959,905 | December 4, 2019 | November 30, 2025 | GANESAN, ANAND K | reporter.nih.gov |
| NGF recruits nerve fibers to reprogram an immunosuppressive microenvironment in melanoma | NIH | National Cancer Institute | 2021 to 2024 | $1,945,149 | February 1, 2020 | January 31, 2025 | WANG, XIAO-FAN | reporter.nih.gov |
| Exploiting a novel regulator of immunometabolism to enhance immunotherapy | NIH | National Cancer Institute | 2022 to 2025 | $1,939,594 | July 1, 2022 | June 30, 2027 | USHERWOOD, EDWARD J | reporter.nih.gov |
| Chronic Mitochondrial Division and Melanoma: Mechanism, Prognosis, and Therapy | NIH | National Cancer Institute | 2022 to 2025 | $1,935,169 | July 15, 2022 | May 31, 2027 | CHIPUK, JERRY EDWARD | reporter.nih.gov |
| Infrared Skin Imaging to Transform Noninvasive Diagnosis and Management of Skin Disease | NIH | Office of the Director, National Institutes of Health | 2021 to 2025 | $1,933,675 | September 14, 2021 | August 31, 2026 | SHMUYLOVICH, LEONID | reporter.nih.gov |
| Defining and targeting epigenetic plasticity-driven drug resistance and immune escape in melanoma | NIH | National Cancer Institute | 2022 to 2025 | $1,926,244 | July 15, 2022 | June 30, 2027 | SMALLEY, KEIRAN | reporter.nih.gov |
| The impact of the dermal ECM microenvironment on cutaneous aging and cancer | NIH | National Institute on Aging | 2023 to 2025 | $1,925,573 | March 15, 2023 | February 28, 2028 | FISHER, GARY J | reporter.nih.gov |
| Therapeutic strategies for treatment of giant congenital melanocytic nevi | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases | 2021 to 2025 | $1,921,106 | August 1, 2017 | July 31, 2028 | FISHER, DAVID E | reporter.nih.gov |
| Role of Heat Shock Protein 70 as a Mediator and Therapeutic Target in T-cell Lymphomas | NIH | National Cancer Institute | 2022 to 2025 | $1,917,273 | July 20, 2022 | June 30, 2027 | ORLOWSKI, ROBERT ZYGMUNT | reporter.nih.gov |
| Mechanisms of Lymphomagenesis of Skin Resident Gamma Delta T cells | NIH | National Cancer Institute | 2022 to 2025 | $1,898,706 | December 13, 2021 | November 30, 2026 | LE POOLE, I. CAROLINE | reporter.nih.gov |
| Roles and regulation of transcriptional reprogramming in squamous carcinogenesis | NIH | National Cancer Institute | 2022 to 2025 | $1,892,832 | August 1, 2022 | July 31, 2027 | SCHOBER, MARKUS | reporter.nih.gov |
| Improvement of cellular immunotherapy during dysbiosis- Resubmission | NIH | National Cancer Institute | 2021 to 2025 | $1,891,918 | September 15, 2021 | August 31, 2026 | DINGS, RUUD P.M. | reporter.nih.gov |
| Preventing MAPK inhibitor resistance in melanoma by targeting genomic instability and immune resistance | NIH | National Cancer Institute | 2021 to 2025 | $1,884,180 | September 4, 2013 | June 30, 2026 | LO, ROGER S | reporter.nih.gov |
| Melanoma: Metabolic Biomarkers of Response to Targeted Therapy | NIH | National Cancer Institute | 2021 to 2024 | $1,875,811 | March 1, 2020 | February 28, 2026 | NATH, KAVINDRA | reporter.nih.gov |
| Innate NLRC4 signaling controls adaptive immune responses | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $1,874,689 | June 20, 2023 | May 31, 2028 | SUTTERWALA, FAYYAZ S. | reporter.nih.gov |
| GCDH Addiction in Melanoma | NIH | National Cancer Institute | 2022 to 2024 | $1,859,149 | July 1, 2022 | September 30, 2024 | RONAI, ZEEV A. | reporter.nih.gov |
| A digital intervention to improve skin self-examination among melanoma survivors | NIH | National Cancer Institute | 2023 to 2025 | $1,854,574 | April 1, 2022 | March 31, 2027 | MANNE, SHARON L | reporter.nih.gov |
| Mechanism for arsenic induced carcinogenesis | NIH | National Institute of Environmental Health Sciences | 2021 to 2025 | $1,853,908 | August 1, 2017 | November 30, 2028 | STATES, J CHRISTOPHER | reporter.nih.gov |
| Rewired Signaling at the Nexus of Melanoma Metastasis and Resistance | NIH | National Cancer Institute | 2024 to 2025 | $1,828,436 | August 1, 2024 | July 31, 2031 | RONAI, ZEEV A. | reporter.nih.gov |
| Nevus associated microRNAs as mediators of BRAF-induced growth arrest and biomarkers of melanoma progression | NIH | National Cancer Institute | 2021 to 2025 | $1,826,736 | August 24, 2021 | July 31, 2026 | JUDSON-TORRES, ROBERT LAIRD | reporter.nih.gov |
| Tumor-derived extracellular vesicles in the pre-metastatic niche. | NIH | National Cancer Institute | 2021 to 2025 | $1,821,912 | August 1, 2017 | August 31, 2029 | DECLERCK, YVES A | reporter.nih.gov |
| Metastatic Clonal Heterogeneity and its Impact on Melanoma Therapeutic Resistance | NIH | National Cancer Institute | 2021 to 2024 | $1,819,435 | May 1, 2020 | April 30, 2026 | HUGO, WILLY | reporter.nih.gov |
| Dissecting the role of hypoxia in T cell differentiation in cancer | NIH | National Cancer Institute | 2023 to 2025 | $1,812,664 | January 1, 2023 | December 31, 2027 | DELGOFFE, GREG M. | reporter.nih.gov |
| Senescence-on-a-chip: Building a microphysiological 3D skin model | NIH | National Cancer Institute | 2024 to 2025 | $1,809,500 | August 5, 2022 | July 31, 2026 | CHRISTIANO, ANGELA M | reporter.nih.gov |
| Applying pathomics to establish a biosignature for aggressive skin melanoma | NIH | National Cancer Institute | 2022 to 2025 | $1,808,280 | May 1, 2021 | April 30, 2027 | SAENGER, YVONNE MARGARET | reporter.nih.gov |
| Optimization of a personalized skin cancer risk intervention for at-risk young adults | NIH | National Cancer Institute | 2023 to 2025 | $1,806,355 | April 1, 2023 | March 31, 2028 | WU, YELENA PING | reporter.nih.gov |
| Development of Potent and non-toxic rexinoids to prevent non-melanoma skin cancer | NIH | National Cancer Institute | 2023 to 2025 | $1,799,831 | March 7, 2023 | February 29, 2028 | ATIGADDA, VENKATRAM REDDY | reporter.nih.gov |
| Reprogramming of the stromal microenvironment in melanoma progression and therapeutic escape | NIH | National Cancer Institute | 2021 to 2025 | $1,797,224 | June 15, 2021 | May 31, 2027 | ZHANG, YUHANG | reporter.nih.gov |
| The role of And-1 in nucleotide excision repair | NIH | National Cancer Institute | 2022 to 2025 | $1,791,325 | February 17, 2022 | January 31, 2027 | ZHU, WENGE | reporter.nih.gov |
| VLA-4–targeted 67Cu-LLP2A preconditioning enhances efficacy of T-cell-based adoptive immunotherapy | NIH | National Cancer Institute | 2023 to 2025 | $1,788,311 | July 5, 2023 | June 30, 2028 | PATEL, RAVI BHASKER | reporter.nih.gov |
| Twist1 as a Target for Prevention and Treatment of Cutaneous Squamous Cell Carcinoma | NIH | National Cancer Institute | 2021 to 2025 | $1,780,213 | July 1, 2021 | December 31, 2026 | DIGIOVANNI, JOHN | reporter.nih.gov |
| The Oncogene Activated Mitochondrial Unfolded Protein Response Regulates Senescence Biology | NIH | National Cancer Institute | 2023 to 2025 | $1,778,295 | April 3, 2023 | March 31, 2028 | CHIPUK, JERRY EDWARD | reporter.nih.gov |
| Regulation of epidermal growth and differentiation through mRNA export | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases | 2022 to 2025 | $1,760,596 | August 2, 2022 | May 31, 2027 | SEN, GEORGE L | reporter.nih.gov |
| Allosteric inhibitors targeting oncogenic BRAF V600E dimers | NIH | National Cancer Institute | 2021 to 2024 | $1,760,127 | December 1, 2019 | November 30, 2024 | GAVATHIOTIS, EVRIPIDIS | reporter.nih.gov |
| PyroTIMER Technology: Enabling T-Cell Persistence in Immunosuppressive Tumor Microenvironments | NIH | National Cancer Institute | 2024 to 2025 | $1,747,620 | September 23, 2024 | August 31, 2026 | BAGATI, ARCHIS | reporter.nih.gov |
| Therapy with fecal microbiota transplantation and immune checkpoint blockade for solid tumors | NIH | National Cancer Institute | 2022 to 2025 | $1,735,364 | June 16, 2022 | May 31, 2027 | ZAROUR, HASSANE M | reporter.nih.gov |
| Mechanisms of BAP1 activity in human cancer development | NIH | National Cancer Institute | 2021 to 2024 | $1,733,898 | December 13, 2019 | November 30, 2025 | CARBONE, MICHELE | reporter.nih.gov |
| Image Deeper with Synthetic Waves: A Novel Non-Invasive Optical Approach for Skin Lesion Assessment at Multiple Scales | NIH | National Institute on Drug Abuse | 2025 | $1,732,297 | September 1, 2025 | August 31, 2027 | WILLOMITZER, FLORIAN | reporter.nih.gov |
| Ablating Liver Metastases with SBRT to Enhance Immune Checkpoint Blockade in Melanoma | NIH | National Cancer Institute | 2023 to 2025 | $1,722,266 | May 5, 2023 | April 30, 2028 | LAWRENCE, THEODORE S | reporter.nih.gov |
| The genomic landscape and evolution of cutaneous squamous cell carcinoma | NIH | National Cancer Institute | 2022 to 2025 | $1,707,881 | September 22, 2022 | August 31, 2027 | SHAIN, ALAN HUNTER | reporter.nih.gov |
| Unraveling the regulatory circuits that drive Merkel cell carcinoma | NIH | National Cancer Institute | 2021 to 2025 | $1,699,585 | August 10, 2021 | July 31, 2027 | PADI, MEGHA | reporter.nih.gov |
| Epigenetic enhancer control in maintaining homeostasis and preventing carcinogenesis in the epidermis | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases | 2021 to 2024 | $1,689,356 | July 15, 2020 | June 30, 2025 | CAPELL, BRIAN | reporter.nih.gov |
| Immune Therapy for Brain Metastasis | NIH | National Cancer Institute | 2023 to 2025 | $1,683,722 | April 18, 2023 | March 31, 2028 | JILAVEANU, LUCIA BEATRICE | reporter.nih.gov |
| Combining senescence-inducing and senolytic agents to improve melanoma therapy | NIH | National Cancer Institute | 2021 to 2025 | $1,682,618 | December 1, 2023 | November 30, 2025 | VILGELM, ANNA E | reporter.nih.gov |
| Optimizing pre-analytic sample handling for high throughput TCR sequencing in cutaneous T cell lymphoma | NIH | National Cancer Institute | 2021 to 2024 | $1,669,583 | September 1, 2020 | May 31, 2026 | CLARK, RACHAEL ANN | reporter.nih.gov |
| The integrated stress response and the microenvironment in melanoma progression | NIH | National Cancer Institute | 2022 to 2025 | $1,645,104 | January 1, 2022 | December 31, 2026 | KOUMENIS, CONSTANTINOS | reporter.nih.gov |
| Two photon fluorescence microscopy for dermatologic surgery and biopsy | NIH | National Cancer Institute | 2021 to 2025 | $1,638,998 | April 1, 2021 | March 31, 2026 | GIACOMELLI, MICHAEL GENE | reporter.nih.gov |
| Circadian clock disruption: A risk factor for environmental carcinogenesis | NIH | National Institute of Environmental Health Sciences | 2021 to 2025 | $1,629,351 | August 28, 2020 | October 31, 2026 | GADDAMEEDHI, SHOBHAN | reporter.nih.gov |
| Therapeutically harnessing anti-viral resident memory T cells in solid tumors | NIH | National Cancer Institute | 2023 to 2025 | $1,618,880 | January 1, 2023 | December 31, 2027 | ROSATO, PAMELA | reporter.nih.gov |
| Mechanisms of UV-Mediated Melanoma Development | NIH | National Cancer Institute | 2021 to 2024 | $1,616,093 | September 4, 2020 | May 31, 2026 | BURD, CHRISTIN E | reporter.nih.gov |
| Developing new therapeutic strategies for brain metastasis | NIH | National Cancer Institute | 2023 to 2025 | $1,609,412 | February 1, 2023 | January 31, 2028 | HERNANDO, EVA | reporter.nih.gov |
| UCHL5 as a regulator and therapeutic target in metastatic melanoma | NIH | National Cancer Institute | 2021 to 2024 | $1,608,800 | August 1, 2020 | April 30, 2026 | RAI, KUNAL | reporter.nih.gov |
| Lipid programs in melanocyte transformation | NIH | National Cancer Institute | 2021 to 2025 | $1,606,364 | March 1, 2020 | February 28, 2026 | OVERHOLTZER, MICHAEL H. | reporter.nih.gov |
| Understanding PPARgamma signaling in melanoma brain metastasis | NIH | National Cancer Institute | 2021 to 2024 | $1,602,434 | December 1, 2019 | October 31, 2024 | CHEN, QING | reporter.nih.gov |
| Novel TYRO3 inhibitors for treatment of cancer | NIH | National Cancer Institute | 2021 to 2025 | $1,600,201 | April 1, 2021 | March 31, 2027 | WANG, XIAODONG | reporter.nih.gov |
| Signaling importance of ‘functionless’ lyso-PAF, an inactive form of platelet activating factor, in melanoma with mutant Nras | NIH | National Cancer Institute | 2022 to 2025 | $1,590,243 | February 23, 2010 | January 31, 2027 | CHEN, JING | reporter.nih.gov |
| Metabolic and epigenetic dependencies in melanomas during metastasis and targeted-drug resistance | NIH | National Cancer Institute | 2021 to 2024 | $1,582,220 | July 1, 2014 | March 31, 2026 | PUIGSERVER, PERE | reporter.nih.gov |
| Structural and Functional Characterization of RhoGEF Regulation Using Nanodiscs to Assemble Membrane-associated Signaling Scaffolds | NIH | National Institute of General Medical Sciences | 2022 to 2025 | $1,577,420 | August 1, 2022 | June 30, 2027 | CASH, JENNIFER NICOLE | reporter.nih.gov |
| Epiproteomics of Sezary Syndrome | NIH | National Cancer Institute | 2022 to 2024 | $1,560,839 | June 1, 2020 | May 31, 2026 | ELENITOBA-JOHNSON, KOJO S. J. | reporter.nih.gov |
| Novel Methods for Identifying Genetic Interactions for Cancer Prognosis | NIH | National Cancer Institute | 2021 to 2024 | $1,555,447 | July 1, 2016 | June 30, 2025 | MA, SHUANGGE | reporter.nih.gov |
| A High-Throughput Model for Human Melanoma | NIH | National Cancer Institute | 2021 to 2025 | $1,553,468 | April 13, 2007 | June 30, 2026 | HOLMEN, SHERI L | reporter.nih.gov |
| The role of regulation and subcellular localization of GTP biosynthesis in melanoma invasion and metastasis | NIH | National Cancer Institute | 2023 to 2025 | $1,534,928 | August 30, 2023 | July 31, 2028 | NIKIFOROV, MIKHAIL | reporter.nih.gov |
| Eradication of Escaped Variant Tumor Cells for Cancer Immunotherapy | NIH | National Cancer Institute | 2022 to 2025 | $1,533,120 | January 1, 2021 | August 31, 2026 | LU, YONG | reporter.nih.gov |
| Novel focused ultrasound enhanced calreticulin-nanoparticle for immune primed melanoma immunotherapy | NIH | National Cancer Institute | 2023 to 2025 | $1,525,979 | June 4, 2019 | July 31, 2027 | RANJAN, ASHISH | reporter.nih.gov |
| Identifying novel therapies targeting Merkel cell carcinoma and tumor microenvironment | NIH | National Cancer Institute | 2022 to 2025 | $1,511,555 | July 14, 2022 | June 30, 2027 | GAO, LING | reporter.nih.gov |
| Exploiting the distinct genomics and signaling of colorectal cancers to effectively target ERK | NIH | National Cancer Institute | 2021 to 2024 | $1,502,540 | December 10, 2018 | November 30, 2024 | YAEGER, RONA | reporter.nih.gov |
| Therapeutic Mechanism of CD47 Blockade in Suppressing Melanoma Metastasis | NIH | National Cancer Institute | 2021 to 2025 | $1,501,311 | April 20, 2020 | March 31, 2026 | BOIKO, ALEXANDER D | reporter.nih.gov |
| Regulation of interferon signaling in melanoma by the cohesin complex protein STAG2 via 3D genome organization | NIH | National Cancer Institute | 2023 to 2025 | $1,501,310 | September 1, 2022 | August 31, 2027 | ZHENG, BIN | reporter.nih.gov |
| Merkel cell polyomavirus infection, host response, and viral oncogenic mechanism | NIH | National Cancer Institute | 2022 to 2025 | $1,497,331 | April 1, 2015 | November 30, 2026 | YOU, JIANXIN | reporter.nih.gov |
| Role of AMPK in melanoma brain metastasis | NIH | National Cancer Institute | 2023 to 2025 | $1,497,263 | January 1, 2023 | December 31, 2027 | ZHENG, BIN | reporter.nih.gov |
| New Strategies for Treatment of NRAS Mutant Melanoma after Progression on Immune Checkpoint Inhibitors | NIH | National Cancer Institute | 2021 to 2024 | $1,494,321 | August 19, 2005 | September 30, 2025 | RICHMOND, ANN | reporter.nih.gov |
| Applying Genomic Dosimeters of UV Damage to Predicting Skin Cancer Risk | NIH | National Institute of Environmental Health Sciences | 2021 to 2024 | $1,494,169 | May 15, 2019 | February 28, 2026 | BRASH, DOUGLAS E | reporter.nih.gov |
| Characterizing oncogenic function of ITCH in melanoma | NIH | National Cancer Institute | 2021 to 2025 | $1,491,935 | August 1, 2021 | July 31, 2027 | WAN, LIXIN | reporter.nih.gov |
| Role of Perivascular Mesenchymal Stem Cells (pMSCs) in the Bone Marrow Niche and the Extracellular Matrix in the Control of Skeletal Metastasis | NIH | National Cancer Institute | 2021 to 2025 | $1,487,614 | September 1, 2020 | May 31, 2026 | SOMOZA, RODRIGO ALFONSO | reporter.nih.gov |
| Investigating the PD-L1:NLRP3 signaling axis as a tumor intrinsic mechanism of adaptive resistance to anti-PD-1 antibody immunotherapy | NIH | National Cancer Institute | 2021 to 2024 | $1,483,568 | August 1, 2020 | January 31, 2025 | HANKS, BRENT ALLEN | reporter.nih.gov |
| Role of metabolic crosstalk in determining immunity during tumor progression | NIH | National Cancer Institute | 2023 to 2025 | $1,477,010 | July 14, 2023 | June 30, 2028 | ANDERSON, ANA C | reporter.nih.gov |
| Linking Genetic, Epigenetic and Signaling Mechanisms of Oncogene Addiction | NIH | National Cancer Institute | 2021 to 2025 | $1,474,583 | May 1, 2021 | April 30, 2027 | FALLAHI-SICHANI, MOHAMMAD | reporter.nih.gov |
| Tissue Damage-Driven Squamous Cell Carcinoma | NIH | National Cancer Institute | 2021 to 2025 | $1,470,745 | January 1, 2021 | January 30, 2025 | SOUTH, ANDREW | reporter.nih.gov |
| KLF-mediated coordination of signaling and epigenetic mechanisms in the skin | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases | 2021 to 2024 | $1,465,497 | February 1, 2020 | January 31, 2026 | MILLAR, SARAH E. | reporter.nih.gov |
| Molecular Mechanisms Underlying the Prevention of BCC Resistance | NIH | National Institute of Environmental Health Sciences | 2021 to 2024 | $1,458,000 | April 7, 2020 | January 31, 2025 | BICKERS, DAVID RINSEY | reporter.nih.gov |
| Mechanism For Merkel Cell Polyomavirus Persistence | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $1,453,906 | January 10, 2024 | November 30, 2028 | CHANG, YUAN | reporter.nih.gov |
| Targeted therapies in cutaneous melanoma | NIH | National Cancer Institute | 2021 to 2024 | $1,448,655 | July 14, 2014 | May 31, 2026 | APLIN, ANDREW ERIC | reporter.nih.gov |
| Study of Anti-Tumor Immunity and Tissue Resident Memory Cell Development by NKG2D and Ribosomal Protein S6 Signaling in T cells | NIH | National Cancer Institute | 2021 to 2024 | $1,441,104 | July 14, 2021 | February 28, 2025 | GUEVARA-PATINO, JOSE ALEJANDRO | reporter.nih.gov |
| Merkel cell polyomavirus HLA class I epitopes for generating therapeutic T cell-based cancer immunotherapy | NIH | National Cancer Institute | 2024 to 2025 | $1,438,870 | January 9, 2024 | December 31, 2028 | KESKIN, DERIN B | reporter.nih.gov |
| Adhesive regulation during cell migration | NIH | National Cancer Institute | 2022 to 2025 | $1,432,752 | June 10, 2000 | November 30, 2026 | HUTTENLOCHER, ANNA | reporter.nih.gov |
| Expanding the Therapeutic Window of Nanoparticle STING Agonists for Cancer Immunotherapy | NIH | National Cancer Institute | 2021 to 2025 | $1,430,039 | August 21, 2020 | April 30, 2027 | WILSON, JOHN TANNER | reporter.nih.gov |
| Role of lipid metabolism in CD8+ T cell ferroptosis | NIH | National Cancer Institute | 2023 to 2025 | $1,429,382 | September 19, 2023 | August 31, 2028 | YI, QING | reporter.nih.gov |
| Mechanisms of cancer mutations | NIH | National Cancer Institute | 2023 to 2025 | $1,423,519 | December 1, 2022 | November 30, 2027 | PFEIFER, GERD P | reporter.nih.gov |
| Regulation of Human Tumorigensis by Cancer Specific NXF1 Adaptor Proteins | NIH | National Cancer Institute | 2022 to 2025 | $1,420,402 | April 1, 2022 | March 31, 2027 | SEN, GEORGE L | reporter.nih.gov |
| Role and mechanisms of IGF2BP1 in melanoma pathogenesis | NIH | National Cancer Institute | 2021 to 2024 | $1,416,035 | December 2, 2019 | November 30, 2024 | SPIEGELMAN, VLADIMIR S. | reporter.nih.gov |
| ISIC-REPO; ISIC Skin Imaging Repository Enhancements for Promoting Interoperability and Utilization | NIH | National Cancer Institute | 2024 to 2025 | $1,411,293 | April 1, 2024 | March 31, 2029 | HALPERN, ALLAN C | reporter.nih.gov |
| The Role of CD5 in Tumor Immunity | NIH | National Cancer Institute | 2021 to 2024 | $1,408,701 | July 1, 2020 | June 30, 2025 | KLECHEVSKY, EYNAV YAFIT | reporter.nih.gov |
| The CD93 pathway and melanoma therapy | NIH | National Cancer Institute | 2022 to 2025 | $1,397,926 | December 3, 2021 | November 30, 2026 | ZHU, YUWEN | reporter.nih.gov |
| Estrogen receptor beta is a targetable melanoma tumor suppressor | NIH | National Cancer Institute | 2022 to 2025 | $1,391,719 | December 1, 2021 | November 30, 2026 | BURD, CRAIG J | reporter.nih.gov |
| Investigating p16 Loss in Pro-tumorigenic Metabolism | NIH | National Cancer Institute | 2021 to 2024 | $1,388,821 | April 1, 2020 | March 31, 2026 | AIRD, KATHERINE MARIE | reporter.nih.gov |
| Targeting the tumor microenvironment with engineered CD4+ T cells | NIH | National Cancer Institute | 2024 to 2025 | $1,387,760 | August 8, 2024 | July 31, 2029 | VEATCH, JOSHUA R | reporter.nih.gov |
| The Role of Genetic Risk Factors in Keratinocyte Carcinoma Susceptibility | NIH | National Cancer Institute | 2021 to 2025 | $1,387,132 | March 1, 2020 | December 31, 2026 | CHOQUET, HELENE | reporter.nih.gov |
| A hybrid effectiveness-implementation trial to integrate precision skin cancer risk feedback in federally qualified health centers | NIH | National Cancer Institute | 2024 to 2025 | $1,381,782 | September 1, 2024 | August 31, 2029 | KANETSKY, PETER A | reporter.nih.gov |
| Determinants of toxicity and response to immune checkpoint blockade through integrative profiling of T cell clonal dynamics and plasma cell- free DNA | NIH | National Cancer Institute | 2024 to 2025 | $1,377,117 | June 7, 2024 | May 31, 2026 | CHAUDHURI, AADEL | reporter.nih.gov |
| Novel cell therapy approaches for molecularly defined subsets of therapy-resistant melanoma | NIH | National Cancer Institute | 2023 to 2025 | $1,375,717 | September 21, 2023 | August 31, 2028 | KLEBANOFF, CHRISTOPHER AUSTIN | reporter.nih.gov |
| Wounding Therapy and Photocarcinogenesis | NIH | National Institute on Aging | 2022 to 2024 | $1,372,342 | September 1, 2014 | August 31, 2027 | TRAVERS, JEFFREY B. | reporter.nih.gov |
| Targeting Rheostatic Mechanisms of Melanoma Progression | NIH | National Cancer Institute | 2021 to 2024 | $1,370,957 | July 1, 2020 | June 30, 2025 | GROSSMANN, ALLIE H. | reporter.nih.gov |
| Expanding the tumor antigen landscape and maintaining APCs in a T cell-activating state to restore tumor immunity | NIH | National Cancer Institute | 2023 to 2025 | $1,370,839 | May 3, 2023 | April 30, 2028 | DAVILA, EDUARDO V | reporter.nih.gov |
| Identification of Covalent Transcriptional Dependencies in Melanoma | NIH | National Cancer Institute | 2024 to 2025 | $1,368,465 | June 14, 2024 | May 31, 2029 | BAR-PELED, LIRON | reporter.nih.gov |
| Immunogenetic determinants of cancer risk | NIH | National Cancer Institute | 2024 to 2025 | $1,357,514 | June 1, 2024 | May 31, 2029 | SAMSTEIN, ROBERT M | reporter.nih.gov |
| Prebiotic diet intervention to enhance the microbiome and immunotherapy response in melanoma | NIH | National Cancer Institute | 2024 to 2025 | $1,354,877 | August 15, 2024 | July 31, 2029 | DANIEL-MACDOUGALL, CARRIE | reporter.nih.gov |
| A network approach to interrogate cellular plasticity and drug resistance in cancer | NIH | National Cancer Institute | 2024 to 2025 | $1,350,826 | June 15, 2024 | May 31, 2026 | AKHURST, ROSEMARY J | reporter.nih.gov |
| Rewiring T cell exhaustion with immune checkpoint blockade therapy | NIH | National Cancer Institute | 2024 to 2025 | $1,349,992 | August 7, 2024 | July 31, 2029 | BRADLEY, LINDA MAC PHERSON | reporter.nih.gov |
| Regulation of DNA Excision Repair in Chromatin | NIH | National Institute of Environmental Health Sciences | 2021 to 2025 | $1,347,804 | August 1, 2018 | March 31, 2029 | WYRICK, JOHN J | reporter.nih.gov |
| Proteolysis targeting chimera against nuclear receptor NR4A1 for melanoma therapy | NIH | National Cancer Institute | 2024 to 2025 | $1,334,046 | April 15, 2024 | March 31, 2029 | ZHANG, WEIZHOU | reporter.nih.gov |
| The Role of Schwann Cells in the Progression of Melanoma | NIH | National Cancer Institute | 2023 to 2025 | $1,322,543 | January 1, 2023 | December 31, 2027 | BUNIMOVICH, YURI | reporter.nih.gov |
| Interplay of natural killer cells and extracellular matrix proteins in solid cancers | NIH | National Cancer Institute | 2024 to 2025 | $1,321,974 | April 1, 2024 | March 31, 2029 | DEMEHRI, SHADMEHR | reporter.nih.gov |
| Designer extracellular vesicles for cancer therapy | NIH | National Cancer Institute | 2024 to 2025 | $1,308,672 | July 8, 2024 | June 30, 2028 | XU, XIAOWEI | reporter.nih.gov |
| Melanoma Resistance Evolution Atlas (MREA) for identifying combinatorial targets to prevent and reverse MAPKi resistance | NIH | National Cancer Institute | 2024 to 2025 | $1,307,905 | March 1, 2024 | February 28, 2029 | LO, ROGER S | reporter.nih.gov |
| Targeting aberrant anti-apoptotic signaling for prevention of skin cancer | NIH | National Cancer Institute | 2021 to 2024 | $1,301,371 | August 1, 2020 | April 30, 2026 | HANSEN, LAURA A | reporter.nih.gov |
| Mechanisms of Smoothened Activation in Hedgehog Signaling | NIH | National Institute of General Medical Sciences | 2022 to 2025 | $1,292,303 | February 1, 2022 | November 30, 2025 | MANGLIK, AASHISH | reporter.nih.gov |
| Role of the tumor NLRP3 inflammasome in the generation of anti-PD-1 antibody immunotherapy-associated toxicities | NIH | National Cancer Institute | 2021 to 2024 | $1,290,653 | July 20, 2021 | January 31, 2025 | HANKS, BRENT ALLEN | reporter.nih.gov |
| Focal Adhesion Kinase - Tumor Biology and Therapeutics | NIH | National Cancer Institute | 2022 to 2025 | $1,289,832 | September 30, 1996 | January 31, 2027 | MARLOWE, TIMOTHY A | reporter.nih.gov |
| Sustaining antitumor effector CD8+ T cells for cancer therapy | NIH | National Cancer Institute | 2024 to 2025 | $1,285,561 | May 17, 2024 | April 30, 2029 | ZHANG, BIN | reporter.nih.gov |
| Mechanism of action and function of novel secosteroid 20(OH)D3 in the skin | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases | 2021 to 2025 | $1,281,521 | May 1, 2018 | January 30, 2030 | SLOMINSKI, ANDRZEJ T | reporter.nih.gov |
| Molecular mechanisms of allele-specific NRAS signaling and tumorigenesis | NIH | National Cancer Institute | 2024 to 2025 | $1,277,886 | July 1, 2024 | June 30, 2026 | BURD, CHRISTIN E | reporter.nih.gov |
| Melanocyte PDL1 control of UVB-induced IFN-I | NIH | National Cancer Institute | 2024 to 2025 | $1,271,892 | July 8, 2024 | June 30, 2029 | CURIEL, TYLER J. | reporter.nih.gov |
| Preventing UV-induced immunosuppression and skin carcinogenesis with R-carvedilol | NIH | National Cancer Institute | 2022 to 2025 | $1,267,574 | July 1, 2022 | June 30, 2027 | HUANG, YING | reporter.nih.gov |
| Targeting dsRNA sensing and ADAR1 in melanoma | NIH | National Cancer Institute | 2024 to 2025 | $1,263,556 | March 1, 2024 | February 28, 2029 | ISHIZUKA, JEFFREY J. | reporter.nih.gov |
| Role of DeltaNp63 alpha and TIP60 in SCC progression and chemoresistance | NIH | National Cancer Institute | 2024 to 2025 | $1,261,890 | December 7, 2023 | November 30, 2028 | KADAKIA, MADHAVI P | reporter.nih.gov |
| Integrative Targeted Therapy for Melanoma | NIH | National Cancer Institute | 2024 to 2025 | $1,240,815 | April 1, 2024 | March 31, 2030 | YANG, JIN-MING | reporter.nih.gov |
| Combinations of Receptor-Targeted Alpha Radionuclide Therapy and Immune Checkpoint Inhibitors for Melanoma Treatment | NIH | National Cancer Institute | 2023 to 2025 | $1,240,605 | April 1, 2023 | April 2, 2025 | MIAO, YUBIN | reporter.nih.gov |
| Development of CM-HZ01 as a non-alpha-IL2 therapeutic for the treatment of metastatic melanoma | NIH | National Cancer Institute | 2025 | $1,228,902 | January 1, 2025 | April 30, 2027 | COOPER, COLLEEN DOYLE | reporter.nih.gov |
| Dissecting the tumor-intrinsic and -extrinsic roles of TBK1 in tumor immunity | NIH | National Cancer Institute | 2023 to 2024 | $1,226,016 | August 1, 2023 | July 31, 2028 | JENKINS, RUSSELL WILLIAM | reporter.nih.gov |
| The mutational mechanisms shaping melanocytes in human skin | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases | 2023 to 2025 | $1,219,413 | February 17, 2023 | November 30, 2027 | SHAIN, ALAN HUNTER | reporter.nih.gov |
| Bhlhe40 Regulation of T Cell Function During Cancer Immunotherapy | NIH | National Cancer Institute | 2024 to 2025 | $1,213,270 | June 1, 2024 | May 31, 2026 | GUBIN, MATTHEW M. | reporter.nih.gov |
| Combating melanoma with an attenuated bacterial therapeutic | NIH | National Cancer Institute | 2023 to 2024 | $1,212,794 | May 1, 2023 | April 30, 2028 | SONG, JIANXUN JIM | reporter.nih.gov |
| Transcriptional Reprogramming in Melanoma Plasticity | NIH | National Cancer Institute | 2024 to 2025 | $1,209,297 | July 18, 2024 | June 30, 2026 | LIANG, CHENGYU | reporter.nih.gov |
| Lymph Node-Targeted Codelivery of Albumin-Binding Peptide Antigens and Di-Adjuvant for Melanoma Combination Immunotherapy | NIH | National Cancer Institute | 2023 to 2025 | $1,181,605 | August 1, 2022 | June 30, 2027 | ZHU, GUIZHI | reporter.nih.gov |
| Multilevel RCT of Rural Community Sun Safety for Young Children in Sports | NIH | National Cancer Institute | 2024 to 2025 | $1,170,699 | May 1, 2024 | April 30, 2029 | WU, YELENA PING | reporter.nih.gov |
| Development and Pre-Clinical Validation of Quantitative Imaging of Cell State Kinetics (QuICK) for Functional Precision Oncology | NIH | National Cancer Institute | 2023 to 2025 | $1,162,721 | September 12, 2023 | August 31, 2028 | ZANGLE, THOMAS ANDREW | reporter.nih.gov |
| Multivalent Small Circular mRNA Vaccines for Melanoma Combination Immunotherapy | NIH | National Cancer Institute | 2024 to 2025 | $1,140,586 | July 17, 2024 | June 30, 2029 | ZHU, GUIZHI | reporter.nih.gov |
| Differential role of different NAD+ kinase Isoforms in melanoma metastasis | NIH | National Cancer Institute | 2022 to 2024 | $1,136,054 | May 1, 2022 | April 30, 2027 | PISKOUNOVA, ELENA | reporter.nih.gov |
| Regulators of Melanocyte Stem Cell Migration and Melanoma Initiation in Response to Cutaneous UVB Irradiation | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases | 2021 to 2024 | $1,134,507 | April 1, 2020 | March 31, 2025 | WHITE, ANDREW C | reporter.nih.gov |
| Intrinsic and Extrinsic factors regulating competition for active TGFb promote skin memory CD8 T cell fitness | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases | 2024 to 2025 | $1,132,258 | July 20, 2024 | June 30, 2029 | KAPLAN, DANIEL H | reporter.nih.gov |
| CCR4-IL2 Bispecific Immunotoxin for Targeted Therapy of Cutaneous T-Cell Lymphoma | NIH | National Cancer Institute | 2023 to 2025 | $1,124,168 | August 1, 2021 | January 31, 2027 | WANG, ZHIRUI | reporter.nih.gov |
| Development of a novel visualization, labeling, and tracking engine for human anatomy. | NIH | National Cancer Institute | 2025 | $1,116,368 | August 1, 2025 | July 31, 2027 | MOLENDA, MATTHEW ALEXANDER | reporter.nih.gov |
| PRecision IMaging to Evaluate Kaposi Sarcoma (PRIME-KS) | NIH | National Cancer Institute | 2024 to 2025 | $1,098,683 | August 7, 2024 | July 31, 2029 | ODENY, THOMAS | reporter.nih.gov |
| Targeting MCPyV oncogene transcription to suppress tumorigenesis | NIH | National Cancer Institute | 2023 to 2025 | $1,096,572 | July 3, 2023 | June 30, 2028 | YOU, JIANXIN | reporter.nih.gov |
| Dissecting the immunomodulatory effects of NK cells on immune responses to cancer | NIH | National Cancer Institute | 2024 to 2025 | $1,093,243 | September 1, 2024 | August 31, 2029 | BARRY, KEVIN C | reporter.nih.gov |
| A Multi-Level Investigation of US Indoor Tanning PolicyEnactment, Implementation, Compliance, Impact, and Economics | NIH | National Cancer Institute | 2023 to 2024 | $1,086,870 | June 1, 2020 | May 31, 2026 | HECKMAN, CAROLYN | reporter.nih.gov |
| Cancer Cell-Extrinsic and Intrinsic Regulators of Tumorigenesis | NIH | National Cancer Institute | 2021 to 2025 | $1,085,020 | September 2, 2021 | August 31, 2026 | JI, ANDREW | reporter.nih.gov |
| Label-free digital cytopathology using deep-ultraviolet coded ptychography with intrinsic molecular contrast | NIH | National Institute of Biomedical Imaging and Bioengineering | 2023 to 2025 | $1,081,236 | July 1, 2023 | June 30, 2027 | ZHENG, GUOAN | reporter.nih.gov |
| Mechanisms of melanoma brain metastasis by CTCs isolated from patients' blood and CSF | NIH | National Cancer Institute | 2021 to 2024 | $1,054,005 | December 15, 2017 | November 30, 2025 | MARCHETTI, DARIO | reporter.nih.gov |
| The Role of IL-15 in Cutaneous T-cell Lymphoma Progression | NIH | National Cancer Institute | 2023 to 2025 | $1,052,708 | July 20, 2023 | June 30, 2028 | MISHRA, ANJALI | reporter.nih.gov |
| A prognostic mRNA immune signature for resected stage II-III melanoma | NIH | National Cancer Institute | 2022 to 2024 | $1,050,317 | June 13, 2019 | March 31, 2025 | SAENGER, YVONNE MARGARET | reporter.nih.gov |
| Melanoma Immunotherapy with GPR182 blockade | NIH | National Cancer Institute | 2023 to 2025 | $1,049,334 | January 1, 2023 | December 31, 2027 | ZHU, YUWEN | reporter.nih.gov |
| The GPR171 pathway in cancer immunotherapy | NIH | National Cancer Institute | 2023 to 2025 | $1,049,334 | April 25, 2023 | March 31, 2028 | ZHU, YUWEN | reporter.nih.gov |
| Targeting the gut microbiome to inhibit melanoma lymph node metastases | NIH | National Cancer Institute | 2024 to 2025 | $1,045,724 | May 1, 2024 | May 30, 2028 | WARGO, JENNIFER A. | reporter.nih.gov |
| Ultrasmall particle-based solutions for inducing ferroptosis and improving anti-tumor immune responses in cancer | NIH | National Cancer Institute | 2023 to 2024 | $1,045,090 | June 1, 2020 | May 31, 2026 | BRADBURY, MICHELLE S | reporter.nih.gov |
| Skin Cancer Risks and Risk Prediction in Patients with Actinic Keratosis | NIH | National Cancer Institute | 2022 to 2025 | $1,041,612 | April 18, 2022 | March 31, 2027 | WEHNER, MACKENZIE RACHEL | reporter.nih.gov |
| Immunotherapeutic targeting of MIF-dependent chaperone activity | NIH | National Cancer Institute | 2023 to 2025 | $1,023,531 | April 1, 2023 | March 31, 2028 | MITCHELL, ROBERT A | reporter.nih.gov |
| Analysis of galectin-8 and its ligands in melanoma progression | NIH | National Cancer Institute | 2024 to 2025 | $1,014,525 | May 16, 2024 | April 30, 2029 | DIMITROFF, CHARLES J | reporter.nih.gov |
| Development of LNS8801 for cutaneous melanoma patients who cannot tolerate immunotherapy | NIH | National Cancer Institute | 2025 | $999,960 | January 13, 2025 | December 31, 2026 | GARYANTES, TINA | reporter.nih.gov |
| IntellipulseTM Platform Technology for Effective Delivery of Therapeutic Agents | NIH | National Cancer Institute | 2025 | $984,830 | September 4, 2025 | August 31, 2027 | STRANGE, GARY | reporter.nih.gov |
| Defining the Role of the Cancer Circadian Clock in Tumor Immunity and Tumorigenesis | NIH | National Cancer Institute | 2023 to 2025 | $978,202 | January 1, 1990 | November 30, 2026 | DANG, CHI V. | reporter.nih.gov |
| Rapid 3D POC digital cancer pathology by unique confocal microscopy instrumentation and downstream AI: a simple, efficient, robust direct-to-digital approach to meet market demand | NIH | National Cancer Institute | 2025 | $978,154 | June 18, 2025 | May 31, 2027 | GAREAU, DANIEL SUMMER | reporter.nih.gov |
| Targeting Unique Meyloid Populations to Overcome Anti-PD-1 Resistance Conferred by Specific Cancer Mutations | NIH | National Cancer Institute | 2021 to 2024 | $962,495 | July 1, 2020 | June 30, 2025 | MILLER, BRIAN C | reporter.nih.gov |
| Role of histotripsy synergized CD40 signaling in the re-engineering of cold tumors | NIH | National Cancer Institute | 2023 to 2025 | $946,644 | September 1, 2022 | August 31, 2028 | RANJAN, ASHISH | reporter.nih.gov |
| Epigenetic Regulation of Cutaneous Tumorigenesis | NIH | National Cancer Institute | 2021 to 2024 | $943,052 | August 1, 2020 | July 31, 2025 | CHEN, DAVID | reporter.nih.gov |
| tRNA modification reprogramming and translational remodeling in cancer | NIH | National Cancer Institute | 2025 | $922,755 | August 28, 2025 | July 31, 2030 | GREGORY, RICHARD I. | reporter.nih.gov |
| Defining impact of in situ activation of CD40 and type 1 interferon signaling on theTME and systemic T cell immunity in murine models and cancer patients | NIH | National Cancer Institute | 2024 to 2025 | $920,408 | May 1, 2024 | April 30, 2029 | BEG, AMER AZIZ | reporter.nih.gov |
| Investigating Transcriptional Elongation and Nuclear RNA Surveillance in Melanoma | NIH | National Cancer Institute | 2021 to 2025 | $919,990 | April 1, 2021 | March 31, 2027 | INSCO, MEGAN LEIGH | reporter.nih.gov |
| Investigating the role of the microbiota in enhancing memory T cell function during caloric restriction to promote melanoma control | NIH | National Cancer Institute | 2022 to 2024 | $904,050 | July 6, 2020 | March 31, 2026 | COLLINS, NICHOLAS | reporter.nih.gov |
| Advanced machine learning to empower ultra-sensitive liquid biopsy in melanoma and non-small cell lung cancer | NIH | National Cancer Institute | 2023 to 2025 | $877,791 | July 4, 2023 | June 30, 2028 | WIDMAN, ADAM | reporter.nih.gov |
| Wounding Therapy and Photocarcinogenesis | NIH | National Institute on Aging | 2025 | $877,297 | September 1, 2014 | August 31, 2027 | TRAVERS, JEFFREY B. | reporter.nih.gov |
| Investigating p16 Loss in Pro-tumorigenic Metabolism | NIH | National Cancer Institute | 2025 | $874,892 | April 1, 2020 | August 31, 2027 | AIRD, KATHERINE MARIE | reporter.nih.gov |
| A dyadic digital skin cancer prevention intervention for adolescents and their parents | NIH | National Cancer Institute | 2025 | $861,930 | August 7, 2025 | July 31, 2028 | HECKMAN, CAROLYN | reporter.nih.gov |
| Genomic biomarkers for cutaneous T-cell Lymphoma | NIH | National Cancer Institute | 2022 to 2024 | $861,358 | October 1, 2022 | January 31, 2026 | LIM, MEGAN S. | reporter.nih.gov |
| Effect of the plantar skin microenvironment on tumor metastasis and drug tolerance | NIH | National Cancer Institute | 2024 to 2025 | $852,164 | September 11, 2024 | August 31, 2029 | REBECCA, VITO WILLIAM | reporter.nih.gov |
| The mechanism of extra-visual circadian photoentrainment in mammals | NIH | National Institute of General Medical Sciences | 2024 to 2025 | $838,555 | January 1, 2024 | December 31, 2027 | BUHR, ETHAN D | reporter.nih.gov |
| Identification of cancer neoepitope-specific T cells using novel high-throughput hydrogel based platforms | NIH | National Cancer Institute | 2024 to 2025 | $835,309 | February 8, 2024 | January 31, 2027 | SCHNECK, JONATHAN P | reporter.nih.gov |
| High dimensional digital pathology to investigate the tumor micro environment and its impact on response to therapy | NIH | National Cancer Institute | 2021 to 2024 | $833,168 | September 1, 2020 | August 31, 2025 | MALIGA, ZOLTAN | reporter.nih.gov |
| Harnessing the therapeutic potential of histotripsy focused ultrasound-induced immunogenic cancer cell death | NIH | National Cancer Institute | 2024 to 2025 | $817,263 | August 3, 2024 | May 31, 2028 | CHO, CLIFFORD | reporter.nih.gov |
| Preventing Melanoma Metastasis by Targeting Lipid Vulnerabilities in Lymph | NIH | National Cancer Institute | 2024 to 2025 | $814,991 | June 5, 2024 | May 31, 2029 | UBELLACKER, JESSALYN | reporter.nih.gov |
| Harnessing the repetitive genome for cancer immunotherapy | NIH | National Cancer Institute | 2023 to 2025 | $806,256 | August 1, 2023 | July 31, 2028 | GRIFFIN, GABRIEL K. | reporter.nih.gov |
| PVSRIPO in melanoma | NIH | National Cancer Institute | 2021 to 2024 | $794,128 | April 1, 2020 | March 31, 2025 | BEASLEY, GEORGIA | reporter.nih.gov |
| Arsenic and other co-metals in the San Carlos Apache drinking water | NIH | National Cancer Institute | 2021 to 2025 | $785,110 | September 1, 2021 | August 31, 2026 | SAMUEL-NAKAMURA, CHRISTINE | reporter.nih.gov |
| Investigating the role of GAPDHS in melanoma metabolism and metastasis | NIH | National Cancer Institute | 2023 to 2025 | $779,256 | July 1, 2023 | June 30, 2028 | GILL, JENNIFER GIBSON | reporter.nih.gov |
| Targeting Oncogenic NRAS, BRAF plus PI3'-Kinase Signaling for Melanoma Therapy | NIH | National Cancer Institute | 2024 to 2025 | $770,000 | April 1, 2013 | March 31, 2029 | MCMAHON, MARTIN | reporter.nih.gov |
| Improving decision-making in patients with resectable melanoma and pre-existing autoimmune disease considering immune checkpoint inhibition | NIH | National Cancer Institute | 2021 to 2024 | $758,305 | April 16, 2020 | March 31, 2026 | LOPEZ-OLIVO, MARIA DE LOS ANGELES | reporter.nih.gov |
| Engineered microtumor arrays for development of combination therapies | NIH | National Cancer Institute | 2021 to 2024 | $754,564 | September 9, 2020 | June 30, 2025 | KILIAN, KRISTOPHER ALAN | reporter.nih.gov |
| Integrative Approach to Comprehensive Analysis of High Throughput Data on a Cancer Center Level | NIH | National Cancer Institute | 2021 to 2025 | $751,310 | September 15, 2016 | August 31, 2026 | KOSSENKOV, ANDREW V | reporter.nih.gov |
| The role of MER/PROS1 in promoting stromal induced emergence from metastatic melanoma dormancy | NIH | National Cancer Institute | 2023 to 2025 | $747,000 | September 1, 2022 | April 30, 2026 | FANE, MITCHELL EDWARD | reporter.nih.gov |
| Discovery of PD-1/PDL-1 inhibitors from marine microbial natural products | NIH | National Cancer Institute | 2021 to 2024 | $741,335 | July 14, 2020 | June 30, 2025 | FENICAL, WILLIAM | reporter.nih.gov |
| Measuring and manipulating metabolic fluxes in the tumor microenvironment | NIH | National Cancer Institute | 2023 to 2025 | $739,764 | September 1, 2022 | August 31, 2026 | BARTMAN, CAROLINE | reporter.nih.gov |
| Investigating the PD-L1:NLRP3 signaling axis as a tumor intrinsic mechanism of adaptive resistance to anti-PD-1 antibody immunotherapy | NIH | National Cancer Institute | 2024 to 2025 | $737,879 | August 1, 2020 | August 31, 2027 | HANKS, BRENT ALLEN | reporter.nih.gov |
| A novel pathway to overcome resistance to immunotherapy in melanoma | NIH | National Cancer Institute | 2024 to 2025 | $732,000 | July 1, 2024 | June 30, 2029 | NORA VAZ SALEIRO, DIANA | reporter.nih.gov |
| The role of stem-like CD8 T-cells in the abscopal response | NIH | National Cancer Institute | 2023 to 2025 | $727,395 | September 1, 2023 | August 31, 2028 | BUCHWALD, ZACHARY SCOTT | reporter.nih.gov |
| Biomaterials-based metabolic rescue of dendritic cells for vaccine design | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $724,324 | January 1, 2021 | January 31, 2026 | ACHARYA, ABHINAV | reporter.nih.gov |
| MAIT cell: microbiome crosstalk in antitumor immunity | NIH | National Cancer Institute | 2024 to 2025 | $713,700 | December 15, 2023 | November 30, 2028 | TOBIN, RICHARD | reporter.nih.gov |
| Neoadjuvant SEMA4D/ICB therapy for melanoma | NIH | National Cancer Institute | 2025 | $709,554 | April 1, 2025 | March 31, 2030 | PAULOS, CHRYSTAL M | reporter.nih.gov |
| Determining the role of neutrophils in anti-tumor immunity and immune-related adverse events in the context of T cell-based therapies | NIH | National Cancer Institute | 2025 | $702,748 | March 17, 2025 | January 31, 2030 | MERGHOUB, TAHA | reporter.nih.gov |
| A soft magnetoelastic microneedle patch for rapid skin cancer screening | NIH | National Cancer Institute | 2024 to 2025 | $701,812 | April 1, 2024 | March 31, 2029 | CHEN, JUN | reporter.nih.gov |
| Practical Randomized Controlled Trial of Artificial Intelligence for Melanoma Diagnosis (PRACTA-MEL) | NIH | National Cancer Institute | 2025 | $700,611 | March 11, 2025 | February 28, 2030 | ROTEMBERG, VERONICA MIRIAM | reporter.nih.gov |
| Mechanism-informed identification of causal enhancer variants | NIH | National Human Genome Research Institute | 2025 | $694,900 | August 11, 2025 | June 30, 2029 | FARLEY, EMMA KIRSTEN | reporter.nih.gov |
| Improving prognosis prediction and therapy selection for cutaneous squamous cell carcinomas using artificial intelligence | NIH | National Institute of Biomedical Imaging and Bioengineering | 2024 | $693,156 | August 1, 2024 | July 31, 2027 | LOTTER, WILLIAM EDWARD | reporter.nih.gov |
| Evaluating Pathways Involved in Melanoma Initiation | NIH | National Cancer Institute | 2025 | $679,604 | August 1, 2025 | July 31, 2030 | ZON, LEONARD IRA | reporter.nih.gov |
| Use of a non-human primate model to define the role of T cell immune responses in persistent Kaposi sarcoma-associated herpesvirus infection and Kaposi sarcoma pathogenesis | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2024 | $672,032 | February 1, 2023 | June 30, 2024 | MUTSVUNGUMA, LORRAINE ZVICHAPERA | reporter.nih.gov |
| Elucidating the functional role and therapeutic potential of GPCR kinase 2 in primary and therapy-resistant basal cell carcinoma | NIH | National Cancer Institute | 2025 | $669,949 | August 15, 2025 | July 31, 2030 | MYERS, BENJAMIN | reporter.nih.gov |
| Improving Mucosal Melanoma Therapy by Harnessing the Immunogenicity of r3LCMV | NIH | National Cancer Institute | 2025 | $667,553 | January 1, 2025 | December 31, 2029 | POLLACK, SETH M | reporter.nih.gov |
| Microfluidic technology to isolate tumoricidal T-cells from peripheral blood | NIH | National Cancer Institute | 2023 to 2025 | $655,173 | August 1, 2023 | July 31, 2026 | SHIRURE, VENKTESH | reporter.nih.gov |
| SESAME: Sun Exposure and Activities after Skin CAncer: Optimization of Mhealth IntErventions | NIH | National Cancer Institute | 2024 to 2025 | $651,635 | September 13, 2024 | August 31, 2027 | ALSHURAFA, NABIL | reporter.nih.gov |
| Modulating the localization and persistence of microbial neoantigen vaccine vectors to enhance therapeutic efficacy | NIH | National Cancer Institute | 2025 | $638,120 | August 1, 2025 | May 31, 2030 | ARPAIA, NICHOLAS | reporter.nih.gov |
| Defining mechanisms of how immune checkpoint inhibitor-associated bacteria modulate tumor immunity in cancer | NIH | National Cancer Institute | 2025 | $636,222 | April 1, 2025 | March 31, 2030 | MEISEL, MARLIES | reporter.nih.gov |
| Role of Merkel cell polyomavirus small T antigen in persistent infection | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $634,981 | June 17, 2025 | May 31, 2030 | SHUDA, MASAHIRO | reporter.nih.gov |
| Patient oriented research and mentoring program in dermatologic diseases | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases | 2022 to 2025 | $625,843 | May 2, 2023 | August 31, 2026 | ASGARI, MARYAM MANDANA | reporter.nih.gov |
| High-throughput and multiplex single-molecule quantification and sorting of single EV | NIH | National Cancer Institute | 2025 | $625,756 | August 12, 2025 | July 31, 2028 | ISSADORE, DAVID AARON | reporter.nih.gov |
| Investigating CREB5-driven mechanisms of immune therapy resistance | NIH | National Cancer Institute | 2025 | $620,820 | December 11, 2024 | December 31, 2029 | MANGUSO, ROBERT THOMAS | reporter.nih.gov |
| Improving the platelet-mediated immune checkpoint inhibitor delivery for treating triple-negative breast cancer | NIH | National Cancer Institute | 2025 | $619,764 | January 10, 2025 | December 31, 2029 | HU, QUANYIN | reporter.nih.gov |
| Synthetic Compartments to Rewire Inflammatory Signaling and Augment Immune Cell Function | NIH | National Institute of Biomedical Imaging and Bioengineering | 2025 | $616,897 | August 8, 2025 | July 31, 2027 | GOOD, MATTHEW CHARLTON | reporter.nih.gov |
| Development of small molecule selective inhibitors of neuronal nitric oxide synthase (nNOS) for melanoma treatment | NIH | National Cancer Institute | 2025 | $610,415 | June 23, 2025 | May 31, 2030 | YANG, SUN | reporter.nih.gov |
| Optimization of Tannic Acid Lipid Nanoparticles for a Therapeutic mRNA Vaccine Against Melanoma | NIH | National Institute of Biomedical Imaging and Bioengineering | 2023 to 2025 | $601,122 | August 1, 2023 | July 31, 2026 | FENTON, OWEN S | reporter.nih.gov |
| Characterization of relation between tissue viscoelasticity and tumor progression in aging tissues | NIH | National Institute on Aging | 2022 to 2025 | $583,226 | September 15, 2021 | August 31, 2027 | PARK, SEUNGMAN | reporter.nih.gov |
| Dissecting the tumor-intrinsic and -extrinsic roles of TBK1 in tumor immunity | NIH | National Cancer Institute | 2025 | $569,782 | August 1, 2025 | July 31, 2028 | JENKINS, RUSSELL WILLIAM | reporter.nih.gov |
| Elucidating the role of tumor cell-intrinsic hypoxia inducible factor (HIF)-1α and HIF-2α pathway activation in tumor immune evasion | NIH | National Cancer Institute | 2023 to 2025 | $566,208 | June 12, 2023 | May 31, 2027 | TRUJILLO, JONATHAN A | reporter.nih.gov |
| Mechanisms of non-genetic variation in melanoma | NIH | National Cancer Institute | 2022 to 2024 | $550,940 | September 1, 2020 | August 31, 2025 | GARG, SALIL | reporter.nih.gov |
| Structure-function studies of LAG3 interactions with antibodies and cellular ligands | NIH | National Cancer Institute | 2025 | $549,962 | April 1, 2025 | March 31, 2030 | LUCA, VINCENT CHRISTOPHER | reporter.nih.gov |
| Utilization of a novel dissimilarity approach to identify a novel mechanism of Merkel cell polyomavirus small tumor antigen nuclear import responsible for the development of Merkel cell carcinoma | NIH | National Cancer Institute | 2025 | $547,875 | September 22, 2025 | August 31, 2028 | DYE, KRISTINE NICOLE | reporter.nih.gov |
| Enhancing Melanoma TIL Efficacy with Multifactor mRNA-Mediated T Cell Reprogramming | NIH | National Cancer Institute | 2023 to 2024 | $538,582 | July 1, 2023 | August 22, 2024 | KATZ, SAMUEL G | reporter.nih.gov |
| Mentoring in mHealth and Social Networking Interventions for CVD Risk Reduction | NIH | National Heart, Lung, and Blood Institute | 2021 to 2024 | $517,154 | April 7, 2015 | December 31, 2025 | PAGOTO, SHERRY L. | reporter.nih.gov |
| Recurrence and Resistance in the Aging Melanoma Microenvironment | NIH | National Cancer Institute | 2025 | $510,431 | July 1, 2025 | June 30, 2030 | WEERARATNA, ASHANI T | reporter.nih.gov |
| Regulation and function of subcellular RNA localization in neural crest cells and their derivatives | NIH | Eunice Kennedy Shriver National Institute of Child Health & Human Development | 2024 to 2025 | $497,935 | August 1, 2024 | July 31, 2027 | NORRIS, MEGAN L | reporter.nih.gov |
| Manipulating Lipid Metabolism to Reverse Immune Dysfunction in Solid Cancers | NIH | National Cancer Institute | 2025 | $496,391 | December 3, 2024 | November 30, 2029 | THAXTON, JESSICA E | reporter.nih.gov |
| Developing and testing a mobile health intervention to promote sun protection behaviors and skin examination among Hispanics | NIH | National Institute on Minority Health and Health Disparities | 2024 to 2025 | $494,389 | April 15, 2022 | January 31, 2027 | NIU, ZHAOMENG | reporter.nih.gov |
| Exploring palmitoylation dynamics: impacts on Cadherin-Catenin adhesion and lipid metabolism in the progression of melanoma lung metastasis | NIH | National Cancer Institute | 2025 | $487,468 | September 1, 2025 | August 31, 2030 | CHEN, SHUYANG | reporter.nih.gov |
| Interrogating the role of GTP metabolism in Rac1-driven phenotypes in melanoma | NIH | National Cancer Institute | 2024 to 2025 | $484,281 | September 20, 2022 | July 31, 2027 | WOLFF, DAVID W | reporter.nih.gov |
| Kinase Signaling in Epidermal Homeostasis and Early Neoplasia | NIH | National Cancer Institute | 2024 | $479,217 | August 1, 2024 | July 31, 2029 | LEE, CAROLYN S. | reporter.nih.gov |
| Genome-wide chromatin structure and function in Kaposi Sarcoma tissue | NIH | National Cancer Institute | 2025 | $476,754 | July 11, 2025 | June 30, 2028 | MIRANDA, JJ | reporter.nih.gov |
| Dissecting clonal diversity in melanoma to overcome therapy resistance andmetastasis | NIH | National Cancer Institute | 2021 to 2024 | $476,124 | April 6, 2020 | March 31, 2025 | REBECCA, VITO WILLIAM | reporter.nih.gov |
| A Phase I Proof-of-Concept Study of CBL0137 Combined with Ipilimumab and Nivolumab Therapy in Locally Advanced or Metastatic Melanoma | NIH | National Cancer Institute | 2023 to 2024 | $472,408 | July 1, 2023 | June 30, 2025 | ASTSATUROV, IGOR | reporter.nih.gov |
| Is ERBB4 a Driver of BRAF WT Melanomas? | NIH | National Cancer Institute | 2024 | $471,175 | January 1, 2024 | December 31, 2026 | RIESE, DAVID J. | reporter.nih.gov |
| Investigating novel targets for topical immunoprevention of keratinocytic skin cancer | NIH | National Cancer Institute | 2025 | $462,092 | August 1, 2025 | July 31, 2027 | DICKINSON, SALLY E | reporter.nih.gov |
| Light-directed therapy of squamous cell head and neck cancer with a novel dual-acting chemotherapeutic. | NIH | National Cancer Institute | 2023 to 2025 | $461,186 | August 3, 2023 | July 31, 2025 | HARTMAN, MATTHEW C | reporter.nih.gov |
| Kinase Signaling in Epidermal Homeostasis and Early Neoplasia | NIH | National Cancer Institute | 2025 | $457,633 | August 1, 2024 | July 31, 2029 | LEE, CAROLYN S. | reporter.nih.gov |
| Stress-induced immunosuppression via downregulation of interferon in triple negative breast cancer | NIH | National Cancer Institute | 2024 to 2025 | $456,919 | July 1, 2024 | June 30, 2029 | GANDHI, SHIPRA | reporter.nih.gov |
| Immune-Related Adverse Events in Melanoma Patients Receiving Adjuvant Immune Checkpoint Inhibitor Therapy | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $455,472 | August 18, 2021 | July 31, 2026 | HASSAN, NOHA ABDELWAHAB HASSAN ALI | reporter.nih.gov |
| Tumor Intrinsic Regulation of Immune Evasion Pathways in Breast Cancer | NIH | National Cancer Institute | 2021 to 2024 | $452,687 | May 12, 2021 | April 30, 2026 | ROSENBAUM, SHEERA | reporter.nih.gov |
| Directing Cytokine Specificity Through Co-translational Carrier Coupling | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2024 | $449,459 | November 8, 2022 | October 31, 2024 | HUANG, YINA HSING | reporter.nih.gov |
| Identifying recurrent driver mutations in skin cancers by targeted UV damage sequencing | NIH | National Institute of Environmental Health Sciences | 2023 to 2024 | $448,500 | March 10, 2023 | February 28, 2026 | WYRICK, JOHN J | reporter.nih.gov |
| Targeting melanoma promoting RNA modification pathway for melanoma therapy. | NIH | National Cancer Institute | 2025 | $442,236 | January 1, 2025 | December 31, 2029 | WAJAPEYEE, NARENDRA | reporter.nih.gov |
| The role of immunosuppression and environmental exposures on incident and subsequent keratinocyte carcinoma risk after solid organ transplant | NIH | National Cancer Institute | 2025 | $441,578 | May 1, 2025 | April 30, 2030 | KAPLAN, DAVID E | reporter.nih.gov |
| Skin Lesion Archive and Annotation for Fusion and Earlier Skin Cancer Detection | NIH | National Cancer Institute | 2024 | $440,011 | April 3, 2024 | March 31, 2027 | STANLEY, RONALD J | reporter.nih.gov |
| Metabolic adaptations in melanoma brain metastasis | NIH | National Cancer Institute | 2024 to 2025 | $435,827 | January 1, 2024 | December 31, 2025 | HERNANDO, EVA | reporter.nih.gov |
| Tetraacylated lipid A enhancement of checkpoint blocking cancer immunotherapy | NIH | National Cancer Institute | 2024 to 2025 | $435,827 | December 4, 2023 | November 30, 2025 | KASPER, DENNIS L. | reporter.nih.gov |
| Targeting a PHGDH metabolic vulnerability in melanoma | NIH | National Cancer Institute | 2024 | $433,256 | May 16, 2024 | April 30, 2026 | KARRETH, FLORIAN | reporter.nih.gov |
| Exploring anti-sense RNAs in melanocyte transformation and melanoma formation | NIH | National Cancer Institute | 2025 | $433,256 | September 1, 2025 | August 31, 2027 | KARRETH, FLORIAN | reporter.nih.gov |
| Mechanisms of augmented UVB immunosuppressive responses by polyaromatic hydrocarbons | NIH | National Institute of Environmental Health Sciences | 2022 to 2024 | $432,815 | September 1, 2022 | August 31, 2025 | SAHU, RAVI PRAKASH | reporter.nih.gov |
| TERT epigenetic and genomic variants in stage II melanoma as biomarkers of outcome | NIH | National Cancer Institute | 2023 to 2024 | $425,922 | February 1, 2023 | January 31, 2026 | POLSKY, DAVID | reporter.nih.gov |
| Unraveling Vascular Mediated Immune Exclusion in Melanoma | NIH | National Cancer Institute | 2024 | $422,971 | June 15, 2024 | May 31, 2026 | KIM, MINAH | reporter.nih.gov |
| A Novel Vaccine Adjuvant KOR-selective Small Molecule Agonist | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $420,730 | July 1, 2024 | May 31, 2026 | YOU, ZHAOYANG | reporter.nih.gov |
| Leveraging combination histotripsy tumor ablation and N-dihydrogalactochitosan immunostimulation to advance osteosarcoma therapy | NIH | National Cancer Institute | 2025 | $419,080 | August 1, 2025 | July 31, 2027 | TUOHY, JOANNE | reporter.nih.gov |
| Understanding how the interaction between Lag3 deficiency and hypercholesterolemia impact anti-tumor immunity and cardiovascular disease in a melanoma model | NIH | National Cancer Institute | 2023 to 2024 | $418,787 | April 1, 2023 | March 31, 2025 | RODRIGUEZ, ANNABELLE | reporter.nih.gov |
| Boosting Oncolytic HSV Immunotherapy by Enabling Necroptosis | NIH | National Cancer Institute | 2025 | $416,040 | July 7, 2025 | June 30, 2027 | GUO, HONGYAN | reporter.nih.gov |
| Precision Tumor Sampling of Melanoma Using Laser Microbiopsy | NIH | National Cancer Institute | 2024 to 2025 | $413,832 | August 8, 2024 | July 31, 2027 | PAREKH, SAPUN H | reporter.nih.gov |
| Harnessing the potential of pharmacological small molecules to amplify VSV-based oncolytic viral therapy | NIH | National Cancer Institute | 2024 | $408,966 | July 5, 2024 | June 30, 2027 | CHAMCHEU, JEAN CHRISTOPHER | reporter.nih.gov |
| Improving Accuracy of Next-Generation Microscopy for Early Stage Metastatic Melanoma Detection | NIH | National Cancer Institute | 2024 to 2025 | $406,044 | January 15, 2024 | June 30, 2026 | WARREN, WARREN S | reporter.nih.gov |
| Special Public T Cell Receptor Sequences that Predict Outcomes for Cancer Patients | NIH | National Cancer Institute | 2023 to 2024 | $402,050 | January 1, 2023 | December 31, 2025 | POLLACK, SETH M | reporter.nih.gov |
| Cell intrinsic and extrinsic effects of zinc metabolism in therapy resistant melanoma | NIH | National Cancer Institute | 2025 | $400,461 | April 1, 2025 | September 1, 2025 | AIRD, KATHERINE MARIE | reporter.nih.gov |
| Next Generation Gene-Gun Delivered DNA and RNA Immunotherapeutic Vaccines for Melanoma. | NIH | National Cancer Institute | 2023 to 2024 | $400,000 | September 21, 2023 | August 31, 2025 | FRIZZELL, HANNAH | reporter.nih.gov |
| Mini-reflectance confocal microscope (Mini-RCM) for aiding skin cancer diagnosis and treatment | NIH | National Cancer Institute | 2025 | $400,000 | February 1, 2025 | January 31, 2027 | KANG, DONGKYUN | reporter.nih.gov |
| A Novel Lentivector for Enhanced In Vivo Delivery of T Cell Receptors for Cell Therapy for Stage IV Melanoma | NIH | National Cancer Institute | 2025 | $400,000 | September 15, 2025 | August 31, 2026 | JOHNSON, DAVID SCOTT | reporter.nih.gov |
| Targeting Endogenous Retrovirus Regulation for Augmenting Cancer Immunotherapy | NIH | National Cancer Institute | 2022 to 2025 | $399,974 | August 1, 2020 | June 30, 2026 | VAN DEN EYNDE, MEAGHAN K. | reporter.nih.gov |
| Targeted Delivery of Tumor Antigen esaRNA to the Spleen for Cancer Immunotherapy | NIH | National Cancer Institute | 2025 | $399,300 | September 10, 2025 | August 31, 2026 | CHAHAL, JASDAVE | reporter.nih.gov |
| Unraveling the Connection: How Metabolism Shapes Mammalian Persister Survival | NIH | National Cancer Institute | 2025 | $398,282 | April 18, 2025 | March 31, 2030 | ORMAN, MEHMET A. | reporter.nih.gov |
| Lectikines for Immunotherapy against Ovarian Cancer | NIH | National Cancer Institute | 2024 to 2025 | $397,465 | February 1, 2024 | January 31, 2027 | MATOBA, NOBUYUKI | reporter.nih.gov |
| Targeting the SKP2 Axis for Anti-melanoma Therapy | NIH | National Cancer Institute | 2025 | $395,509 | April 4, 2025 | March 31, 2030 | INUZUKA, HIROYUKI | reporter.nih.gov |
| Differential role of different NAD+ kinase Isoforms in melanoma metastasis-Relinquishment | NIH | National Cancer Institute | 2025 | $395,509 | May 1, 2022 | April 30, 2027 | PISKOUNOVA, ELENA | reporter.nih.gov |
| Leveraging cancer-evolved resistance mechanisms to enhance EZH2 activity in adoptive T cells | NIH | National Cancer Institute | 2024 | $393,401 | June 1, 2024 | May 31, 2026 | TACKETT, ALAN | reporter.nih.gov |
| Overcoming therapy resistance in melanoma | NIH | National Cancer Institute | 2024 to 2025 | $391,314 | April 1, 2024 | March 31, 2027 | SHENG, ZHI | reporter.nih.gov |
| Novel Strategy to Augmenting Immunotherapy against Melanoma | NIH | National Cancer Institute | 2024 to 2025 | $390,252 | March 1, 2024 | February 28, 2027 | YANG, JIN-MING | reporter.nih.gov |
| Targeting Rheostatic Mechanisms in Melanoma | NIH | National Cancer Institute | 2025 | $388,875 | July 1, 2020 | June 30, 2027 | GROSSMANN, ALLIE H. | reporter.nih.gov |
| Deciphering the role of tumor-macrophage crosstalk during metastatic dissemination to the peritoneum | NIH | National Cancer Institute | 2022 to 2025 | $388,120 | September 1, 2021 | May 31, 2026 | HAN, JICHANG | reporter.nih.gov |
| Develop IL13Ra1 for diagnosis of early-stage mycosis fungoides | NIH | National Cancer Institute | 2024 to 2025 | $387,402 | January 8, 2024 | December 31, 2026 | FUSCHIOTTI, PATRIZIA | reporter.nih.gov |
| Discovery of PPI inhibitors for the FAK FAT domain | NIH | National Cancer Institute | 2023 to 2024 | $385,717 | December 9, 2022 | November 30, 2024 | MARLOWE, TIMOTHY A | reporter.nih.gov |
| PD-1/PD-L1 signaling at the interface between immune and stem cell crosstalk | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $384,250 | May 1, 2025 | April 30, 2027 | HARRIS, MELISSA L | reporter.nih.gov |
| Leveraging gnotobiotic models to study the gut microbiota and anti-tumor immunity | NIH | National Cancer Institute | 2021 to 2024 | $383,591 | September 12, 2018 | February 28, 2025 | FESSLER, JESSICA LYNN | reporter.nih.gov |
| A novel gene-based immunotherapy inducing melanoma destruction | NIH | National Cancer Institute | 2024 to 2025 | $382,432 | March 15, 2024 | February 28, 2027 | MICHAEL, KATJA | reporter.nih.gov |
| In vivo label free optical imaging of immune cells in human skin | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases | 2023 to 2024 | $373,723 | March 1, 2023 | December 31, 2025 | BALU, MIHAELA | reporter.nih.gov |
| Programmable 'all-in-one' RNA as a molecular scaffold for targeted combinatorial innate immune activation | NIH | National Institute of Biomedical Imaging and Bioengineering | 2024 to 2025 | $373,402 | January 1, 2024 | December 31, 2026 | WU, CONNIE | reporter.nih.gov |
| Functional Landscape of Glycosylation in Skin Cancer | NIH | National Cancer Institute | 2023 to 2024 | $361,055 | February 1, 2023 | January 31, 2026 | KUDELKA, MATTHEW ROBERT | reporter.nih.gov |
| Targeting epigenetic abnormalities to inhibit cutaneous squamous cell carcinoma | NIH | National Cancer Institute | 2025 | $360,281 | July 31, 2025 | August 31, 2028 | KAWASUMI, MASAOKI | reporter.nih.gov |
| Phase I Therapeutic Award: A Novel Engineered Bacterial Anticancer Immunotherapy for Merkel Cell Carcinoma | NIH | National Cancer Institute | 2024 | $354,966 | February 21, 2024 | February 20, 2025 | HAN, SONGLEE | reporter.nih.gov |
| Explainable Artificial Intelligence for Melanoma Recurrence Prediction via Integrative Modeling of Multiplexed Imaging with Transcriptomics and Histopathology | NIH | National Cancer Institute | 2024 to 2025 | $352,080 | February 9, 2024 | January 31, 2026 | WAN, GUIHONG | reporter.nih.gov |
| Understanding mitochondrial mutations that drive human tissue aging | NIH | National Institute on Aging | 2024 to 2025 | $347,576 | September 12, 2024 | June 30, 2029 | VANDIVER, AMY R. | reporter.nih.gov |
| Discovery of fused heterocyclic pyrazine based novel anti-mitotic agents for metastatic melanoma | NIH | National Institute of General Medical Sciences | 2024 to 2025 | $346,291 | July 22, 2024 | June 30, 2028 | BANERJEE, SOUVIK | reporter.nih.gov |
| The role of the novel interface cell state in melanoma invasion | NIH | National Cancer Institute | 2023 to 2024 | $346,032 | April 1, 2023 | March 31, 2026 | HUNTER, MIRANDA VICTORIA | reporter.nih.gov |
| Rewired Signaling at the Nexus of Melanoma Metastasis and Resistance | NIH | National Cancer Institute | 2024 | $343,564 | August 1, 2024 | September 30, 2024 | RONAI, ZEEV A. | reporter.nih.gov |
| PTP1b Inhibition Restores the Innate Anti-tumor Response During Chemotherapy | NIH | National Cancer Institute | 2025 | $333,073 | July 1, 2025 | June 30, 2027 | UBIL, ERIC S | reporter.nih.gov |
| Dissecting the Role of Germline Genetics in RAS-Driven Cancers | NIH | National Cancer Institute | 2024 to 2025 | $327,456 | February 1, 2024 | August 31, 2025 | COLLINS, RYAN LEWIS | reporter.nih.gov |
| Improving decision-making for older adults with melanoma | NIH | National Institute on Aging | 2024 | $322,000 | September 15, 2024 | August 31, 2026 | LEE, JAY SOONG-JIN | reporter.nih.gov |
| Analytical and Clinical Validation of an EPIC 900K v2 array-based methylation assay to predict recurrence in stage II melanoma | NIH | National Cancer Institute | 2025 | $310,185 | April 3, 2025 | September 30, 2026 | POLSKY, DAVID | reporter.nih.gov |
| Toward safe, systemic immunotherapies for treatment of metastatic disease: Developing dendritic cell-biased immunomodulators with precise control over magnitude and timing of immune stimulation | NIH | National Cancer Institute | 2023 to 2025 | $307,695 | August 11, 2021 | August 31, 2027 | BHAGCHANDANI, SACHIN | reporter.nih.gov |
| Using microsphere technology for the electrochemical measurement of genotoxicity. | NIH | National Institute of Environmental Health Sciences | 2025 | $303,165 | August 19, 2025 | July 31, 2026 | SYKORA, PETER | reporter.nih.gov |
| A Biobased Biodegradable Sunscreen that is Safe, Removes Environmental Impact, is Inclusive of all Skin Tones, and is for the Purpose of Eliminating Disparities in Melanoma Mortality Rates | NIH | National Institute on Minority Health and Health Disparities | 2024 | $293,629 | August 18, 2024 | July 31, 2025 | CAL, ANDREW | reporter.nih.gov |
| Tissue Damage-Driven Squamous Cell Carcinoma | NIH | National Cancer Institute | 2025 | $278,822 | March 1, 2025 | August 31, 2026 | SOUTH, ANDREW | reporter.nih.gov |
| Circulating cell free tumor DNA (ctDNA) in patients with immune checkpoint inhibitor associated inflammatory arthritis (ICI-IA): developing a biomarker to assess immunosuppressive drug safety | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases | 2025 | $267,423 | September 16, 2025 | August 31, 2028 | BASS, ANNE R | reporter.nih.gov |
| Regulation and function of subcellular RNA localization in neural crest cells and their derivatives | NIH | Eunice Kennedy Shriver National Institute of Child Health & Human Development | 2023 to 2024 | $264,780 | July 20, 2023 | July 31, 2024 | NORRIS, MEGAN L | reporter.nih.gov |
| Investigating the Role of Cancer-Associated Fibroblasts in Immunodetection of Mycosis Fungoides | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases | 2024 to 2025 | $260,280 | June 13, 2024 | June 30, 2026 | JOHNSON, COURTNEY MICHELE | reporter.nih.gov |
| Targeting mitochondrial vulnerabilities to drive intrinsic melanoma immunogenicity | NIH | National Cancer Institute | 2024 to 2025 | $257,596 | April 4, 2024 | July 1, 2025 | LIANG, JIAXIN | reporter.nih.gov |
| Characterization of the Symptom Experience of Patients with Cutaneous Melanoma Receiving Immune Checkpoint Inhibitor Therapy | NIH | National Cancer Institute | 2025 | $249,000 | February 1, 2024 | August 31, 2028 | HARRIS, CAROLYN STIGGE | reporter.nih.gov |
| Targeting mitochondrial vulnerabilities to drive intrinsic melanoma immunogenicity | NIH | National Cancer Institute | 2025 | $249,000 | April 4, 2024 | July 31, 2028 | LIANG, JIAXIN | reporter.nih.gov |
| Dissecting the Role of Germline Genetics in RAS-Driven Cancers | NIH | National Cancer Institute | 2025 | $248,999 | February 1, 2024 | August 31, 2028 | COLLINS, RYAN LEWIS | reporter.nih.gov |
| L-fucose-mediated enrichment of memory CD4+T cells and enhanced anti-melanoma immunity | NIH | National Cancer Institute | 2024 | $236,321 | February 1, 2024 | January 31, 2026 | LAU, ERIC KIRK | reporter.nih.gov |
| Targeting Tumor-Driven Immune Tolerance to Overcome Resistance to Hedgehog Inhibition | NIH | National Cancer Institute | 2025 | $230,711 | April 1, 2025 | March 31, 2027 | KIM, ARIANNA L | reporter.nih.gov |
| Intestinal NOD2 and the microbiota enhance Coxsackievirus B3 pathogenesis | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $226,641 | December 5, 2024 | November 30, 2026 | KEESTRA-GOUNDER, ARINA MARIJKE | reporter.nih.gov |
| Comparing NK cell profiles within melanoma tumors and pregnancy: Implications for novel immunotherapies | NIH | National Cancer Institute | 2025 | $217,863 | December 1, 2024 | November 30, 2026 | NORMAN, PAUL JOHN | reporter.nih.gov |
| In vivo characterization of keratinocytes in the melanoma microenvironment | NIH | National Cancer Institute | 2021 to 2024 | $206,302 | July 1, 2021 | June 30, 2025 | MA, YILUN | reporter.nih.gov |
| DISSECTING THE ROLE OF THE IMMUNE MICROENVIRONMENT IN MELANOMA BONE METASTASIS | NIH | National Cancer Institute | 2025 | $198,103 | February 1, 2025 | January 31, 2027 | HERNANDO, EVA | reporter.nih.gov |
| Controlled Antigen Delivery for Prophylactic Cancer Vaccination | NIH | National Cancer Institute | 2024 to 2025 | $194,213 | September 1, 2023 | April 30, 2028 | POGOSTIN, BRETT | reporter.nih.gov |
| Elucidating the Function of LRP1 in APOE-mediated Suppression of Melanoma Metastasis | NIH | National Cancer Institute | 2021 to 2024 | $187,905 | January 11, 2021 | May 16, 2024 | ADAKU, NNEOMA | reporter.nih.gov |
| Title of Project * L-fucose-mediated enrichment of memory CD4+T cells and enhanced anti-melanoma immunity | NIH | National Cancer Institute | 2025 | $182,325 | February 1, 2024 | August 31, 2026 | LAU, ERIC KIRK | reporter.nih.gov |
| Fibrotic remodeling of lymph nodes disrupts T cell function in fibrosis and cancer | NIH | National Cancer Institute | 2024 to 2025 | $182,098 | January 1, 2024 | May 18, 2025 | BINGHAM, GRACE C | reporter.nih.gov |
| Mechanisms of perivascular melanoma dispersal and survival in the brain | NIH | National Cancer Institute | 2022 to 2025 | $180,232 | January 1, 2022 | December 31, 2025 | WANG, SARAH C | reporter.nih.gov |
| Modulating Human Microbiome Function to Enhance Immune Responses Against Cancer | NIH | National Cancer Institute | 2025 | $179,988 | January 1, 2025 | December 31, 2026 | SONNENBURG, JUSTIN L | reporter.nih.gov |
| The effect of aging on cDC1 function and CD8 T cell immunity in tumors | NIH | National Cancer Institute | 2025 | $176,040 | April 1, 2025 | March 31, 2027 | CHEN, CHANG-YU ALEX | reporter.nih.gov |
| Building Reliable Vision-Language Assistant for Dermatology AI through Modeling Uncertainties in Multimodal LLMs | NIH | National Institute of General Medical Sciences | 2025 | $175,470 | August 12, 2025 | June 30, 2029 | TAO, ZHIQIANG | reporter.nih.gov |
| Electrical impedance dermography as a biomarker for basal and squamous cell carcinoma | NIH | National Cancer Institute | 2025 | $174,939 | January 1, 2025 | December 31, 2026 | GROSSMAN, DOUGLAS | reporter.nih.gov |
| Characterizing the role of SRCAP in Epidermal Homeostasis and Squamous Cell Carcinoma | NIH | National Cancer Institute | 2021 to 2024 | $170,308 | March 1, 2021 | February 28, 2025 | DROLL, STEPHENIE | reporter.nih.gov |
| Epigenetic Regulation of Melanoma-Associated Fibroblast Plasticity | NIH | National Cancer Institute | 2025 | $169,000 | August 1, 2025 | July 31, 2027 | FILIPESCU, DAN | reporter.nih.gov |
| Award of Task Order 3 entitled "A Dual AKT/PDPK1 Inhibitor for Actinic Keratosis and Skin Cancer Prevention in Immunocompromised Individuals" | NIH | National Cancer Institute | 2024 | $166,186 | September 17, 2018 | June 16, 2024 | LYUBIMOV, ALEXANDER | reporter.nih.gov |
| Evaluating a multimodality platform of tissue, blood and advanced imaging-based biomarkers to predict response to neoadjuvant immunotherapy and radiotherapy in melanoma | NIH | National Center for Advancing Translational Sciences | 2025 | $163,310 | September 12, 2025 | September 11, 2027 | MITRA, DEVARATI | reporter.nih.gov |
| Neoantigen-specific T cells in a novel cutaneous squamous cell carcinoma model | NIH | National Cancer Institute | 2023 to 2025 | $161,206 | August 1, 2023 | July 31, 2026 | ADAMS, ANNGELA CHRISTINA | reporter.nih.gov |
| The role of alpha-synuclein in nucleolar DNA double-strand break repair and cellular senescence | NIH | National Institute on Aging | 2023 to 2025 | $161,206 | July 1, 2023 | June 30, 2027 | ARNOLD, MORIAH REBECCA | reporter.nih.gov |
| Spatial Profiling of Melanocytic Tumors and Their Microenvironment | NIH | National Cancer Institute | 2023 to 2024 | $160,500 | July 1, 2023 | June 30, 2025 | KIURU, MAIJA HELENA TUULIA | reporter.nih.gov |
| The frequency and function of Type 3 Innate Lymphoid Cells regulates the melanoma tumor microenvironment | NIH | National Cancer Institute | 2024 to 2025 | $158,324 | July 1, 2024 | June 30, 2026 | O'CONNOR, MARGARET | reporter.nih.gov |
| Stress-induced immunosuppression via downregulation of interferon in triple negative breast cancer | NIH | National Cancer Institute | 2024 | $157,771 | July 1, 2024 | February 28, 2025 | GANDHI, SHIPRA | reporter.nih.gov |
| SWI/SNF in ultraviolet radiation-induced chromatin alterations | NIH | National Institute of Environmental Health Sciences | 2025 | $156,250 | December 20, 2024 | November 30, 2026 | DE LA SERNA, IVANA L | reporter.nih.gov |
| Establishing an in-vivo Sleeping-Beauty Screen to Identify and Characterize Novel Drivers of Melanomagenesis in a Nevi-Prone Zebrafish Model. | NIH | National Cancer Institute | 2025 | $155,500 | July 18, 2025 | June 30, 2027 | KENNY, COLIN P | reporter.nih.gov |
| Novel Immunomodulators for Melanoma Therapy | NIH | National Institute of General Medical Sciences | 2025 | $154,000 | July 18, 2025 | June 30, 2029 | MINOND, DMITRIY | reporter.nih.gov |
| Conditional Agonism: PD1-Dependent Activation of 4-1BB for Enhanced Safety | NIH | National Cancer Institute | 2025 | $153,959 | September 1, 2025 | August 31, 2027 | SANDEY, MANINDER | reporter.nih.gov |
| Development of immunocompetent melanoma brain metastases organoids | NIH | National Cancer Institute | 2024 to 2025 | $153,000 | March 6, 2024 | February 28, 2026 | RODRIGUEZ, ANALIZ | reporter.nih.gov |
| Directed Clonal Evolution of Drug Resistant BRAF Mutant Melanoma for Cross-Sensitization to MAPK Hyperactivation | NIH | National Cancer Institute | 2024 to 2025 | $152,324 | March 1, 2024 | February 28, 2027 | CHO, EUNICE | reporter.nih.gov |
| Gadusol: An ancient sunscreen that protects metazoan development | NIH | National Institute of General Medical Sciences | 2024 to 2025 | $149,348 | September 16, 2024 | September 15, 2026 | JOHNSON, KRISTIN LORETTE | reporter.nih.gov |
| Defining the role of stress granules in cancer initiation | NIH | National Cancer Institute | 2024 to 2025 | $149,348 | August 1, 2024 | July 31, 2027 | DRAKE, KYLE DAVID | reporter.nih.gov |
| Investigating the role of fatty acid metabolism in melanocyte differentiation: Insights into the metabolic requirements of development | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases | 2021 to 2024 | $145,978 | July 1, 2021 | August 31, 2024 | JOHNS, ELEANOR MAY | reporter.nih.gov |
| Immunoediting in Cutaneous Squamous Cell Carcinoma | NIH | National Cancer Institute | 2023 to 2025 | $143,512 | July 1, 2023 | August 31, 2027 | BORDEN, ELIZABETH | reporter.nih.gov |
| Neural Mechanisms Driving Comorbid Parkinson's and Melanoma | NIH | National Cancer Institute | 2022 to 2024 | $143,420 | July 1, 2022 | June 30, 2025 | DEL VALLE, PAMELA | reporter.nih.gov |
| Interrogating the Fgl2-FcgRIIB axis: A novel mechanism mediating apoptosis of tumor-specific memory CD8+ T cells | NIH | National Cancer Institute | 2024 to 2025 | $141,043 | September 1, 2023 | January 2, 2026 | BENNION, KELSEY | reporter.nih.gov |
| Harnessing hotspot specific differences among SF3B1 mutations to define novel mechanisms of tumorigenicity and targetability in solid malignancies | NIH | National Cancer Institute | 2023 to 2025 | $140,795 | July 1, 2023 | June 30, 2026 | BERGMAN, RILEY | reporter.nih.gov |
| Data-driven mechanistic models of morphology-controlled Ras oncogenic signaling | NIH | National Cancer Institute | 2025 | $140,097 | April 1, 2025 | March 31, 2027 | MAZLOOM FARSIBAF, HANIEH | reporter.nih.gov |
| Combining Radiation, Allogeneic Natural Killer Immunotherapy, and PD-L1 blockade in Dogs with Naturally-Occurring Melanoma | NIH | National Cancer Institute | 2023 to 2025 | $136,394 | May 1, 2023 | April 30, 2027 | RAZMARA, ARYANA | reporter.nih.gov |
| DNA repair pathway coordination during damage processing | NIH | National Institute of Environmental Health Sciences | 2023 to 2025 | $131,231 | January 1, 2024 | September 10, 2025 | SCHAICH, MATTHEW ALLEN | reporter.nih.gov |
| Tri-Signal Artificial Antigen Presenting Cells for Cancer Immunotherapy | NIH | National Cancer Institute | 2023 to 2025 | $129,437 | September 1, 2023 | February 28, 2026 | SHANNON, SYDNEY ROSE | reporter.nih.gov |
| HMGB1 in EB-Associated Squamous Cell Carcinoma | NIH | National Cancer Institute | 2023 to 2025 | $128,503 | August 1, 2023 | July 31, 2027 | BUI, KACEY LINNEA GUENTHER | reporter.nih.gov |
| The role of tumor cell-of-origin-specific PDL1 on tumorigenesis and tumor progression | NIH | National Cancer Institute | 2023 to 2025 | $125,143 | August 3, 2023 | August 2, 2027 | ONTIVEROS, CARLOS OSCAR | reporter.nih.gov |
| Influence of Caffeine on Melanoma | NIH | National Cancer Institute | 2022 to 2025 | $114,642 | January 1, 2023 | June 14, 2025 | BRATHWAITE, RODERICK DION | reporter.nih.gov |
| Immune-Related Adverse Events in Melanoma Patients Receiving Adjuvant Immune Checkpoint Inhibitor Therapy | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $113,868 | August 18, 2021 | July 31, 2026 | HASSAN, NOHA ABDELWAHAB HASSAN ALI | reporter.nih.gov |
| Mitochondrial Regulation of Interferon Response in Melanoma | NIH | National Cancer Institute | 2023 to 2025 | $105,504 | August 1, 2023 | December 31, 2025 | JOHNSON, MELISSA | reporter.nih.gov |
| Dissecting the genetic basis of cancer immune evasion in squamous cell carcinoma | NIH | National Cancer Institute | 2024 to 2025 | $100,012 | September 1, 2024 | August 31, 2026 | NICHOLSON, BENJAMIN | reporter.nih.gov |
| Defining tumor and blood-based immunogenomic signatures predicting response to immunotherapy in ovarian cancer | NIH | National Cancer Institute | 2025 | $99,171 | December 1, 2024 | November 30, 2028 | MONSON, KELSEY R | reporter.nih.gov |
| Targeting TEAD in melanoma drug-tolerant persister cells | NIH | National Cancer Institute | 2024 to 2025 | $98,512 | July 5, 2024 | July 4, 2026 | OTT, CONNOR | reporter.nih.gov |
| Elucidating the role of mRNA m6A methylation in tumorigenesis | NIH | National Cancer Institute | 2023 to 2024 | $98,168 | September 1, 2023 | March 14, 2025 | WILKINSON, EMMA ANNE | reporter.nih.gov |
| Mechanism underlying how host B cells empower adoptively transferred Th17 cells with durable tumor immunity | NIH | National Cancer Institute | 2024 to 2025 | $94,266 | February 1, 2024 | December 7, 2025 | COLE, ANNA CAMILLE ELYSE | reporter.nih.gov |
| Investigating the epidermal microenvironment in melanoblast migration and invasion: a novel approach to understanding invasive melanoma | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases | 2024 to 2025 | $92,452 | January 1, 2023 | December 31, 2027 | RICHARDS, DENAY | reporter.nih.gov |
| Development of Lipid Nanoparticles for B-cell Mediated Immunotherapies | NIH | National Cancer Institute | 2025 | $90,765 | December 1, 2024 | November 30, 2028 | SUSIN PIRES, IVAN | reporter.nih.gov |
| Keratin and filament cell-cell junction cooperation in developmental and tumorigenic fate decisions | NIH | National Cancer Institute | 2025 | $90,720 | December 9, 2024 | November 30, 2028 | REDMOND, CATHERINE JULIA | reporter.nih.gov |
| Identifying the Mechanism of Resistance to Immunotherapy in Merkel Cell Carcinoma (for Zachary Reinstein) | NIH | National Cancer Institute | 2024 to 2025 | $88,938 | February 1, 2024 | January 31, 2026 | REINSTEIN, ZACHARY ZALE | reporter.nih.gov |
| Paracrine signaling from keratinocytes establishes a pro-melanoma environment | NIH | National Cancer Institute | 2024 to 2025 | $88,374 | March 1, 2024 | February 28, 2027 | POKORNY, JENNY | reporter.nih.gov |
| The Molecular Mechanism of Genetic Disorders Due to XPD Mutations | NIH | National Institute of General Medical Sciences | 2024 to 2025 | $85,712 | August 1, 2024 | July 31, 2026 | HOAG, ALLYSON LYNNE | reporter.nih.gov |
| Mechanisms of Macrophage-Mediated Immune Evasion in Residual Tumors | NIH | National Cancer Institute | 2024 to 2025 | $84,954 | April 1, 2024 | March 31, 2027 | RAJ, JUDE | reporter.nih.gov |
| Expanding access to perioperative and repurposed drug trials in melanoma and other solid tumors | NIH | National Cancer Institute | 2025 | $83,925 | September 10, 2025 | August 31, 2030 | LOWE, MICHAEL | reporter.nih.gov |
| The influence of lymph node metastasis on local and systemic anti-tumor immunity | NIH | National Cancer Institute | 2024 to 2025 | $83,792 | August 1, 2024 | July 31, 2027 | VENTRE, KATHERINE | reporter.nih.gov |
| The shared and distinct cistromes of YAP and TAZ in melanoma | NIH | National Cancer Institute | 2025 | $81,750 | December 1, 2024 | November 30, 2026 | LANG, DEBORAH | reporter.nih.gov |
| The interface of neurons and cancer | NIH | National Cancer Institute | 2024 to 2025 | $81,222 | December 1, 2024 | August 31, 2026 | LUKASIK, KIMBERLY | reporter.nih.gov |
| Investigating microphthalmia-associated transcription factor (MITF) and growth factors as initiators of melanoma | NIH | National Cancer Institute | 2024 to 2025 | $81,003 | September 1, 2024 | August 31, 2027 | HONGO, RACHEL | reporter.nih.gov |
| Understanding B cell immunity in Merkel cell carcinoma | NIH | National Cancer Institute | 2024 to 2025 | $80,685 | July 1, 2024 | June 30, 2026 | SCHNABEL, JULIA | reporter.nih.gov |
| Merkel cell polyomavirus T-Antigen mediated reprogramming in adult epidermis | NIH | National Cancer Institute | 2024 to 2025 | $80,636 | February 5, 2024 | August 11, 2025 | WEBER, MADISON | reporter.nih.gov |
| Selection of oncogenic Ras mutations through tumor promotion mechanisms | NIH | National Cancer Institute | 2022 to 2024 | $77,326 | December 1, 2022 | October 31, 2024 | BOLLAM, SAUMYA REDDY | reporter.nih.gov |
| Endothelial Cell Cycle Control to Normalize the Tumor Vasculature | NIH | National Cancer Institute | 2024 to 2025 | $76,960 | July 1, 2024 | June 30, 2027 | CAIN, SHELBY | reporter.nih.gov |
| Defining the biochemical properties and implications of NRAS mutant-specific BRAF interactions in melanoma | NIH | National Cancer Institute | 2024 to 2025 | $75,752 | August 1, 2024 | July 31, 2027 | LEW, RACHEL E. | reporter.nih.gov |
| Impact of LAG3 on CD8+ T cell motility and migration in the context of cancer immunotherapy | NIH | National Cancer Institute | 2025 | $75,520 | March 1, 2025 | February 28, 2026 | BAESSLER, ANDREW STEPHEN | reporter.nih.gov |
| Relative and synergistic contributions of PD1 and LAG3 on CD4+ T conventional cells in cancer | NIH | National Cancer Institute | 2025 | $75,520 | December 1, 2025 | November 30, 2027 | MIHALIK, NICOLE | reporter.nih.gov |
| Investigating the role of melanoma-adipocyte cell junctions in heterotypic communication and tumor progression | NIH | National Cancer Institute | 2023 to 2024 | $72,889 | July 13, 2023 | October 9, 2024 | PERLEE, SARAH | reporter.nih.gov |
| Deciphering the mechanisms of nucleolar stress response during MCPyV infection | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $72,320 | August 1, 2024 | July 31, 2026 | PHAM, ALEXANDER MICHAEL | reporter.nih.gov |
| Defining the functional and spatial properties of tumor-specific tumor-infiltrating CD8 T cells | NIH | National Cancer Institute | 2024 to 2025 | $68,980 | May 1, 2024 | February 28, 2026 | AFEYAN, ALEXANDER BADRIG KJELL | reporter.nih.gov |
| Investigating the epidermal microenvironment in melanoblast migration and invasion: a novel approach to understanding invasive melanoma | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases | 2022 to 2024 | $67,612 | January 1, 2023 | May 28, 2024 | RICHARDS, DENAY | reporter.nih.gov |
| ICOS is an important mediator of both resident memory cell formation, and improved durability and persistence of anti-tumor T cells | NIH | National Cancer Institute | 2025 | $54,538 | February 20, 2025 | February 19, 2029 | WITTLING, MEGEN CLAIRE | reporter.nih.gov |
| Studying the role of skin pathobionts in Cutaneous T cell Lymphoma | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $54,538 | September 1, 2025 | August 31, 2028 | GUMINA, MEGAN | reporter.nih.gov |
Organizations
| Organization | Place | NIH awards | NIH amount | NSF awards | NSF amount |
|---|---|---|---|---|---|
| University of Pittsburgh at Pittsburgh | Pittsburgh, PA | 21 | $26.5 million | 0 | $0 |
| New York University School of Medicine | New York, NY | 17 | $25.6 million | 0 | $0 |
| University of Pennsylvania | Philadelphia, PA | 16 | $23.9 million | 0 | $0 |
| Massachusetts General Hospital | Boston, MA | 12 | $20.6 million | 0 | $0 |
| Dana-Farber Cancer Inst | Boston, MA | 11 | $16.9 million | 0 | $0 |
| University of Michigan at Ann Arbor | Ann Arbor, MI | 10 | $16.8 million | 0 | $0 |
| University of TX MD Anderson Can CTR | Houston, TX | 14 | $16.6 million | 0 | $0 |
| Stanford University | Stanford, CA | 8 | $15.2 million | 0 | $0 |
| University of Utah | Salt Lake City, UT | 12 | $15.1 million | 0 | $0 |
| Yale University | New Haven, CT | 10 | $14.4 million | 0 | $0 |
| H. Lee Moffitt Cancer CTR & Res Inst | Tampa, FL | 12 | $14.3 million | 0 | $0 |
| University of California, San Francisco | San Francisco, CA | 8 | $13.6 million | 0 | $0 |
| Sloan-Kettering Inst Can Research | New York, NY | 13 | $13.6 million | 0 | $0 |
| Brigham and Women's Hospital | Boston, MA | 7 | $13.3 million | 0 | $0 |
| University of California Los Angeles | Los Angeles, CA | 7 | $11.4 million | 0 | $0 |
| Columbia University Health Sciences | New York, NY | 10 | $10.9 million | 0 | $0 |
| Institute for Systems Biology | Seattle, WA | 1 | $10.6 million | 0 | $0 |
| Icahn School of Medicine at Mount Sinai | New York, NY | 10 | $10.4 million | 0 | $0 |
| University of Colorado Denver | Aurora, CO | 11 | $10.3 million | 0 | $0 |
| Univ of North Carolina Chapel Hill | Chapel Hill, NC | 8 | $10.1 million | 0 | $0 |
| Weill Medical Coll of Cornell Univ | New York, NY | 8 | $9.8 million | 0 | $0 |
| Johns Hopkins University | Baltimore, MD | 10 | $9.3 million | 0 | $0 |
| Dartmouth College | Hanover, NH | 5 | $8.9 million | 0 | $0 |
| Cedars-Sinai Medical Center | Los Angeles, CA | 5 | $8.2 million | 0 | $0 |
| Northwestern University at Chicago | Chicago, IL | 9 | $8.1 million | 0 | $0 |
| Washington University | Saint Louis, MO | 6 | $8.1 million | 0 | $0 |
| Duke University | Durham, NC | 9 | $8 million | 0 | $0 |
| University of California-Irvine | Irvine, CA | 4 | $7.5 million | 0 | $0 |
| University of Alabama at Birmingham | Birmingham, AL | 5 | $7.4 million | 0 | $0 |
| Fred Hutchinson Cancer Center | Seattle, WA | 3 | $7.2 million | 0 | $0 |
| University of California, San Diego | La Jolla, CA | 5 | $7.1 million | 0 | $0 |
| Wistar Institute | Philadelphia, PA | 5 | $6.9 million | 0 | $0 |
| Children's Hosp of Philadelphia | Philadelphia, PA | 2 | $6.9 million | 0 | $0 |
| Ohio State University | Columbus, OH | 7 | $6.7 million | 0 | $0 |
| University of Southern California | Los Angeles, CA | 2 | $6.4 million | 0 | $0 |
| Thomas Jefferson University | Philadelphia, PA | 5 | $6.4 million | 0 | $0 |
| Boston Immune Technologies and Therapeutics, Inc. | Winchester, MA | 1 | $6.4 million | 0 | $0 |
| Ut Southwestern Medical Center | Dallas, TX | 6 | $6.3 million | 0 | $0 |
| University of Washington | Seattle, WA | 4 | $6 million | 0 | $0 |
| University of Arizona | Tucson, AZ | 7 | $5.9 million | 0 | $0 |
| Sanford Burnham Prebys Medical Discovery Institute | La Jolla, CA | 4 | $5.8 million | 0 | $0 |
| University of Wisconsin-Madison | Madison, WI | 4 | $4.6 million | 0 | $0 |
| Albert Einstein College of Medicine | Bronx, NY | 3 | $4.6 million | 0 | $0 |
| Mayo Clinic Rochester | Rochester, MN | 2 | $4.4 million | 0 | $0 |
| Rutgers Biomedical and Health Sciences | Newark, NJ | 5 | $4.4 million | 0 | $0 |
| University of Kentucky | Lexington, KY | 4 | $4.3 million | 0 | $0 |
| University of Texas at Austin | Austin, TX | 3 | $4.3 million | 0 | $0 |
| University of Virginia | Charlottesville, VA | 5 | $4.2 million | 0 | $0 |
| Pennsylvania State Univ Hershey Med CTR | Hershey, PA | 3 | $4 million | 0 | $0 |
| Wright State University | Dayton, OH | 4 | $3.9 million | 0 | $0 |
| Washington State University | Pullman, WA | 3 | $3.9 million | 0 | $0 |
| Beckman Research Institute/city of Hope | Duarte, CA | 2 | $3.9 million | 0 | $0 |
| La Jolla Institute for Immunology | La Jolla, CA | 1 | $3.5 million | 0 | $0 |
| Cornell University | Ithaca, NY | 2 | $3.5 million | 0 | $0 |
| Research Inst of Fox Chase Can CTR | Philadelphia, PA | 3 | $3.5 million | 0 | $0 |
| Roswell Park Cancer Institute Corp | Buffalo, NY | 2 | $3.4 million | 0 | $0 |
| University of Louisville | Louisville, KY | 3 | $3.3 million | 0 | $0 |
| University of New Mexico Health Scis CTR | Albuquerque, NM | 3 | $3.2 million | 0 | $0 |
| University of Tennessee Health Sci CTR | Memphis, TN | 1 | $3.1 million | 0 | $0 |
| Vanderbilt University | Nashville, TN | 3 | $3.1 million | 0 | $0 |
| Surgivance, Inc. | New York, NY | 2 | $3 million | 0 | $0 |
| Veriskin, Inc. | San Diego, CA | 1 | $3 million | 0 | $0 |
| Methodist Hospital Research Institute | Houston, TX | 2 | $3 million | 0 | $0 |
| Providence Portland Medical Center | Portland, OR | 1 | $3 million | 0 | $0 |
| Baylor College of Medicine | Houston, TX | 1 | $2.9 million | 0 | $0 |
| Boston Children's Hospital | Boston, MA | 3 | $2.8 million | 0 | $0 |
| Oregon Health & Science University | Portland, OR | 3 | $2.6 million | 0 | $0 |
| University of California at Davis | Davis, CA | 4 | $2.5 million | 0 | $0 |
| Rockefeller University | New York, NY | 2 | $2.5 million | 0 | $0 |
| Univ of Arkansas for Med Scis | Little Rock, AR | 3 | $2.4 million | 0 | $0 |
| University of Chicago | Chicago, IL | 5 | $2.4 million | 0 | $0 |
| Georgetown University | Washington, DC | 1 | $2.3 million | 0 | $0 |
| Van Andel Research Institute | Grand Rapids, MI | 2 | $2.2 million | 0 | $0 |
| Case Western Reserve University | Cleveland, OH | 2 | $2.2 million | 0 | $0 |
| Northwestern University | Chicago, IL | 2 | $2.2 million | 0 | $0 |
| Indiana University | Bloomington, IN | 1 | $2.2 million | 0 | $0 |
| Emory University | Atlanta, GA | 6 | $2.1 million | 0 | $0 |
| Phusis Therapeutics, Inc. | La Jolla, CA | 1 | $2.1 million | 0 | $0 |
| Nanometics, LLC | La Jolla, CA | 1 | $2 million | 0 | $0 |
| Lipo-Immuno Tech, LLC | Mount Pleasant, SC | 1 | $2 million | 0 | $0 |
| Sonoval LLC | Gaithersburg, MD | 1 | $2 million | 0 | $0 |
| Enspectra Health, Inc. | Mountain View, CA | 1 | $2 million | 0 | $0 |
| 7 Hills Pharma, LLC | Houston, TX | 1 | $2 million | 0 | $0 |
| Scripps Research Institute, the | La Jolla, CA | 1 | $2 million | 0 | $0 |
| Children's Hospital of Los Angeles | Los Angeles, CA | 1 | $1.8 million | 0 | $0 |
| University of Cincinnati | Cincinnati, OH | 1 | $1.8 million | 0 | $0 |
| George Washington University | Washington, DC | 1 | $1.8 million | 0 | $0 |
| Pyrojas INC | Long Island City, NY | 1 | $1.7 million | 0 | $0 |
| University of Hawaii | Honolulu, HI | 1 | $1.7 million | 0 | $0 |
| University of Rochester | Rochester, NY | 1 | $1.6 million | 0 | $0 |
| North Carolina State University | Raleigh, NC | 1 | $1.6 million | 0 | $0 |
| University of Connecticut | Storrs, CT | 2 | $1.6 million | 0 | $0 |
| Southern California Inst for Res/educ | Long Beach, CA | 1 | $1.5 million | 0 | $0 |
| Harvard Medical School | Boston, MA | 5 | $1.5 million | 0 | $0 |
| Kaiser Foundation Research Institute | Oakland, CA | 1 | $1.4 million | 0 | $0 |
| University of Florida | Gainesville, FL | 2 | $1.4 million | 0 | $0 |
| Creighton University | Omaha, NE | 1 | $1.3 million | 0 | $0 |
| Dartmouth-Hitchcock Clinic | Lebanon, NH | 1 | $1.3 million | 0 | $0 |
| Western University of Health Sciences | Pomona, CA | 1 | $1.3 million | 0 | $0 |
| Celdara Medical, LLC | Lebanon, NH | 1 | $1.2 million | 0 | $0 |
Funding by fiscal year
| Fiscal year | NIH awards | NIH amount | NSF awards | NSF amount |
|---|---|---|---|---|
| 2025 | 397 | $183,801,962 | 0 | $0 |
| 2024 | 410 | $168,972,735 | 0 | $0 |
| 2023 | 297 | $133,877,097 | 0 | $0 |
| 2022 | 211 | $96,152,562 | 0 | $0 |
| 2021 | 137 | $60,093,692 | 0 | $0 |
Open federal funding opportunities
From Grants.gov: notices that funded awards in this table, and open notices on the same agency and assistance listing.
| Open opportunity | Number | Agency | Listing | Closes | Award ceiling | Why it matches |
|---|---|---|---|---|---|---|
| Change of Recipient Organization (Type 7 Parent Clinical Trial Optional) | PA-24-254 | NIH | July 12, 2027 | Not listed | Notice number printed on 12 awards here | |
| NIH Support for Conferences and Scientific Meetings (Parent R13 Clinical Trial Not Allowed) | PA-25-080 | NIH | September 7, 2027 | Not listed | Notice number printed on 1 award here | |
| NCI Research Specialist (Clinician Scientist) Award (R50 Clinical Trial Not Allowed) | PAR-27-089 | NIH | 93.396 | November 2, 2026 | Not listed | Same assistance listing 93.396 as 124 awards here |
| NCI Research Specialist Award for Core and Laboratory-based Scientists (R50 Clinical Trial Not Allowed) | PAR-27-088 | NIH | 93.396 | November 20, 2026 | Not listed | Same assistance listing 93.396 as 124 awards here |
| NIH Research Software Engineer (RSE) Award (R50 Clinical Trials Not Allowed) | RFA-OD-24-011 | NIH | 93.396 | December 4, 2026 | Not listed | Same assistance listing 93.396 as 124 awards here |
| Academic Research Enhancement Award (AREA) for Undergraduate-Focused Institutions (R15 Clinical Trial Required) | PAR-24-214 | NIH | 93.396 | January 7, 2027 | $375,000 | Same assistance listing 93.396 as 124 awards here |
| Population Approaches to Reducing Alcohol-related Cancer Risk (R01 Clinical Trial Optional) | PAR-25-221 | NIH | 93.396 | January 7, 2027 | Not listed | Same assistance listing 93.396 as 124 awards here |
| Single Source: Coordinating Center (CC) for the Small Cell Lung Cancer (SCLC) Consortium (U24 Clinical Trial Not Allowed) | PAR-27-009 | NIH | 93.396 | January 25, 2027 | Not listed | Same assistance listing 93.396 as 124 awards here |
| Carcinogen Hazard Assessment Monographs Program (CHAMP) (R01 Clinical Trial Not Allowed) | RFA-CA-28-013 | NIH | 93.396 | February 9, 2027 | $700,000 | Same assistance listing 93.396 as 124 awards here |
| New Approaches for Measuring Brain Changes Across Longer Timespans (R21 Clinical Trial Optional) | PAR-25-272 | NIH | 93.396 | May 7, 2027 | Not listed | Same assistance listing 93.396 as 124 awards here |
| New Approaches for Measuring Brain Changes Across Longer Timespans (R01 Clinical Trial Optional) | PAR-25-279 | NIH | 93.396 | May 7, 2027 | Not listed | Same assistance listing 93.396 as 124 awards here |
| Advanced Development and Sustainment of Informatics Technologies for Cancer Research and Management (U24 Clinical Trial Optional) | RFA-CA-28-003 | NIH | 93.396 | June 11, 2027 | $600,000 | Same assistance listing 93.396 as 124 awards here |
| Successor-in-Interest (Type 6 Parent Clinical Trial Optional) | PA-24-253 | NIH | 93.396 | July 17, 2027 | Not listed | Same assistance listing 93.396 as 124 awards here |
| Investigator-Focused Award (Parent R35) | PAR-28-037 | NIH | 93.396 | October 4, 2027 | Not listed | Same assistance listing 93.396 as 124 awards here |
| Early-Stage Development of Informatics Technologies for Cancer Research and Management (U01 Clinical Trial Optional) | RFA-CA-27-019 | NIH | 93.396 | October 19, 2027 | $300,000 | Same assistance listing 93.396 as 124 awards here |
| NIH Research Project Grant (Parent R01 Clinical Trial Not Allowed) | PA-25-301 | NIH | 93.396 | January 7, 2028 | Not listed | Same assistance listing 93.396 as 124 awards here |
| NIH Exploratory/Developmental Research Project Grant (Parent R21 Clinical Trial Not Allowed) | PA-25-304 | NIH | 93.396 | January 7, 2028 | Not listed | Same assistance listing 93.396 as 124 awards here |
| NIH Exploratory/Developmental Research Project Grant (Parent R21 Clinical Trial Required) | PA-25-306 | NIH | 93.396 | January 7, 2028 | Not listed | Same assistance listing 93.396 as 124 awards here |
| Molecular Imaging of Inflammation in Cancer (R01 Clinical Trial Not Allowed) | PAR-24-311 | NIH | 93.396 | January 7, 2028 | $500,000 | Same assistance listing 93.396 as 124 awards here |
| Mechanisms that Impact Cancer Risk after Bariatric Surgery (R01 Clinical Trial Optional) | PAR-25-043 | NIH | 93.396 | January 7, 2028 | $500,000 | Same assistance listing 93.396 as 124 awards here |
Updated November 3, 2026. Read from NIH RePORTER ExPORTER and NSF Award Search. Published by NIH and NSF as U.S. government data. NIH awards are fiscal years 2021 to 2025 (NIH files published to 2026-07-09); NSF awards are fiscal years 2022 to 2026 (NSF files published to 2026-11-02). NIH amounts are the total cost of each fiscal year in the window; NSF amounts are the funds obligated in the window. Organizations are matched on the UEI. Open opportunities come from Grants.gov and match on agency and assistance listing number, and on the notice number NIH prints on an award. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.